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ABSTRACT

Antidepressant medications are an effective treatment option for individuals
with depression. However, significantly sub-optimal adherence has been observed in
up to 44% of primary care patients. Almost 40% of patients who discontinue their
medication experience a return of symptoms. Adherence interventions are therefore
important, but often require delivery by highly trained clinicians (e.g. physicians). In
Australia adherence interventions need to have the capacity to be delivered by a
variety of professionals as a diverse range of clinicians (e.g. allied health) provide
services to primary care patients under a number of government funded initiatives.
However, many clinicians lack the requisite knowledge, skills, and beliefs to
facilitate adherence. Addressing this need is important given that clinicians' beliefs
may influence the type of treatment that patients receive, such as whether support is
provided to the patient to use their medication more effectively. Researchers in
Australia and the UK report successful attempts to increase clinicians' skills,
knowledge, and beliefs to facilitate adherence to antipsychotic medication.
Furthermore, when trained clinicians work to facilitate adherence among patients with
psychosis, significant increases in adherence and reductions in psychopathology are
obtained, compared with treatment as usual. There are few studies that focus on
improving medication adherence skills in clinicians working with depressive
disorders.
Study 1 surveyed 72 allied health clinicians working in primary care with
individuals with depression. This study sought to identify clinicians' beliefs about (a)
medications in general, (b) adequacy to facilitate adherence, (c) their role in
facilitating adherence, as well as (d) previous training in adherence strategies, and (e)

self-reported use of use specific adherence strategies. It was hypothesised that more
positive beliefs and previous training would be related to higher reported use of
specific adherence strategies. The degree to which these variables predict selfreported use of adherence strategies was also explored. Results showed clinicians'
beliefs about adequacy and their role in facilitating adherence predicts self-reported
use of adherence strategies. Previously trained clinicians reported significantly more
positive beliefs about adequacy and their role in facilitating adherence.
Study 2 evaluated the impact of a modified version of the Medication Alliance
training program on the knowledge, beliefs and skills of 24 allied health clinicians
working in primary care. It was hypothesised that pre- and post-training measures
would demonstrate increases in clinicians' knowledge, skill, and beliefs related to
enhancing adherence amongst individuals with depression. Results showed significant
increases in knowledge and beliefs to facilitate adherence following training. No
significant increase in skill was found. These results suggest that Medication Alliance
techniques can be successfully delivered to improve the knowledge and beliefs of
allied health cUnicians working in primary care. The next step is to examine the
impact that clinician training has on patient adherence to antidepressant medication.

DEPRESSION: A GLOBAL HEALTH CRISIS

Depression is a major health issue, affecting approximately 5% of the
Australian population at any one time (Australian Bureau of Statistics [ABS], 2001).
In 2001 approximately 800 thousand people living in Australia reported experiencing
problems with mood, including depressive disorders (ABS). Worldwide, depressive
disorders affect approximately 121 million people (World Health Organisation
[WHO], n.d.). Depressive disorders are the leading cause of disability, and the fourth
leading contributor to the global burden of disease (Murray & Lopez, 1996). In 2002,
depressive disorders were the leading cause of burden of disease for females, and the
fourth leading cause for males (WHO, 2003). By the year 2020, depressive disorders
are expected to be the second overall leading contributor to global burden of diseases
for both men and women (Murray & Lopez).
Depressive disorders are defined in the Diagnostic and Statistical Manual of
Mental Disorders,

edition text revision (DSM IV-TR, American Psychiatric

Association [APA], 2000a), as a disturbance in mood, including depressed mood or
loss of interest or pleasure. They include Major Depressive Disorder (MDD),
Dysthymic Disorder (DD), and Depressive Disorder Not Otherwise Specified. In
MDD, a person may experience one or more Major Depressive Episodes, which are
characterised by at least "2 weeks of depressed mood or loss of interest accompanied
by at least four additional symptoms of depression" (APA, p. 345). DD is the
experience of "2 years or more of depressed mood for more days than not,
accompanied by additional depressive symptoms that do not meet criteria for a Major
Depressive Episode" (APA, pp. 345). Depressive Disorder Not Otherwise Specified is

the diagnosis given when depressed mood is a focus of clinical attention but
symptoms do not meet criteria for another Mood Disorder (APA).

Prevalence

Research in primary care settings has found that point prevalence rates for
depressive disorders are almost double that of the prevalence in community samples,
suggesting that depressive disorders are common and under-treated in primary care
settings (Al-Windi, 2005; Steiner et al., 1999). In community samples, point
prevalence for MDD is reported between 2% to 9% (APA, 2000a; Blazer, Kessler,
McGonagle, & Swartz, 1994), while in primary care, point prevalence is reported
between 5% and 20% (Al-Windi; Aragonés et al., 2004; Berardi et al., 2002;
Christensen, Bundgaard, & Bech, 2001; Katon & Schulberg, 1992; MeansChristensen, Amau, Tonidandel, Bramson, & Meagher, 2005; Wittchen & Pittrow,
2002).
Twelve-month prevalence rates among community samples are comparable
with that of primary care and are reported between 2.6% to 12.9% in community
samples (Angst, 1992; Hasin, Goodwin, Stinson, & Grant, 2005; Kessler et al., 1994,
2003) and 8.3% in primary care samples (Wittchen & Pittrow, 2002). Lower
prevalence rates have been reported for DD in comparison to MDD. The DSM IV-TR
reports a point prevalence rate for DD at 3% among the general population (APA,
2000a), primary care studies reporting slightly higher rate of 4.8% (Aragonés et al.,
2004) and 5.1% (Steiner et al., 1999).

Course

Left untreated, the course of depressive disorders can be chronic or patients
may cycle between relapse and remission. Katon et al. (1995) report that
approximately 70% of patients in primary care experienced at least two or more prior
depressive episodes. Up to 25% of people suffering from a depressive disorder
experience a chronic course (Angst, 1997). After experiencing a single episode of
depression, the risk of relapse is reported to be as high as 87% within 15 years (Keller
& Boland, 1998).
DD has a chronic course, with at least a 2-year period of depressive symptoms
without relief from these for more than 2 months (APA, 2000a). MDD can also have a
persistent and chronic course. The DSMIV-TR states that up to 60% of people
suffering from a single episode of Major Depression will experience a second (APA).
This percentage increases with each episode, such that after the second episode 70%
will experience a third, and after the third episode approximately 90% will experience
a fourth (APA). The risk of recurrence in MDD (i.e., the occurrence of new Major
Depressive Episode after a 6 month or longer period where depressive symptoms no
longer meet criteria for MDD; Frank et al., 1991) is reported at around 40%
(Piccinelli & Wilkinson, 1994; Ramana et al., 1995).
In a study of primary care patients, Lin et al. (1998) found 37.1% of patients
experience a return of symptoms within one year or met criteria for MDD at a 19month follow-up assessment. Shea et al. (1992) found that patients with a diagnosis of
MDD experienced recurrence at a rate of between 33% and 50% over an 18-month
follow-up period, dependent on treatment received. In a 3.5-year follow-up of patients
with depressive disorders, it was found that 39.3% of the sample experienced the

recurrence of a Major Depressive Episode (Hoencamp, Haffmans, Griens,
Huijbrechts, & Heycop ten Ham, 2001). The risk of recurrence is said to increase over
time, such that after 10 years the rate of recurrence is 75% (Keller & Boland, 1998;
Piccinelli & Wilkinson, 1994), and up to as high as 87% after 15 years (Keller &
Boland).
A chronic course of MDD (the continuous experience of a Major Depressive
Episode for at least 2 years, with symptom free periods of no longer than 2 months) is
said to be experienced by between 10% to 25% of individuals (Angst, 1997; Piccinelli
& Wilkinson, 1994). In a 10-year follow-up of data from the WHO, 10% of people
experienced a Major Depressive Episode for at least 2 years (Thomicroft & Sartorius,
1993). Keller et al., (1992) found 12% of their sample had experienced a Major
Depressive Episode over a 5-year period, while Hoencamp et al., (2001) found 36%
of their sample had a chronic course.

Impact of Depressive Disorders

Individuals with depressive disorders have an increased risk of suicidal
thoughts and behaviours (Nierenberg et al., 2001). The risk of death by suicide for
individuals with MDD has been reported at 15% (APA, 2000a; Nierenberg et al.). The
WHO estimates approximately 850 thousand suicides each year are related to MDD
(WHO, n.d.). In a study of suicidal ideation among outpatients in the United States,
researchers found the 50% of individuals with treatment-resistant depression (i.e.
individuals with a depressive disorder that has previously not responded to
antidepressant medication) reported suicidal thoughts, while one third reported
significant suicidal thoughts or suicidal behaviours (Papakostas et al., 2003). The

contribution of depression to suicidal behaviour has also been assessed in Australia
(Goldney, 2003). Goldney reported studies of community samples that found 39% to
47% reported suicidal ideation, and 40% of suicide attempts can be accounted for by
depressive disorders.
Not surprisingly, depressive disorders have a significant impact on functioning
and quality of life. Sufferers often experience significantly greater difficulty working
and carrying out day to day duties, impairment in physical and social functioning,
general health concerns, and utilise a greater amount of health services compared with
individuals who do not meet criteria for a depressive disorder (Goldney, Fisher,
Wilson, & Cheok, 2000; Hawthorne, Cheok, Goldney, & Fisher, 2003) or individuals
with a chronic medical condition (Spitzer et al., 1995). Berardi et al. (2002) found that
depression is associated with severe physical illness, disability, and higher rates of
medical consultation among primary care patients. In Australia it is estimated that
disability due to depressive disorders costs the health sector and individual patients in
excess of one billion dollars (Hawthorne et al.). Given the significant impact
depressive disorders have on health globally, and the economic burden they carry, the
enhancement of treatment outcomes is of significant importance.

TREATING DEPRESSIVE DISORDERS

Both the United States and Australian guidelines for the treatment of
depression indicate that antidepressant medication should be considered as a first-line
treatment for depressive disorders, especially in severe, chronic, and relapsing
disorders (APA, 2000b; Ellis & Smith, 2002). In addition, psychological therapies
such as Cognitive Behavioural Therapy and Interpersonal Therapy are suggested as
alternative first-line treatments in the instance of mild to moderate depression or
adjunct interventions in severe depression. Reviews of the literature support the use of
both antidepressant medication and psychological therapies. This combination has
been reported as superior to either treatment used m isolation for effectively reducing
severe depressive symptoms, keeping patients in treatment longer, and thus reducing
the risk of relapse (APA; Friedman et al., 2004; Pampallona, Bollini, Tibaldi,
Kupelnick, & Munizza, 2004; Thase et al., 1997). Relapse in this context has been
defined as the return of symptoms that meet criteria for a Major Depressive Episode
within 6 months of an initial response to antidepressant medication (Frank et al.,
1991),
However, many patients with depressive disorders are treated in primary care
settings where resources to provide such psychological interventions are limited
(Ludman et al., 2003). In fact, the majority of individuals with depressive disorders
seek treatment from their GP (ABS, 2001; Lin et al., 1998). The efficacy of
psychological therapies relies heavily on the skills of the clinician delivering the
therapy, and it has been suggested that psychological therapies should only be
considered when an appropriately skilled clinician is available (Ellis & Smith, 2002).

Pharmacotherapy for Depression

There are many types of antidepressant medications available for the treatment
of depressive disorders. Treatment guidelines state that the efficacy across different
types of antidepressant medication is mostly equal, and recommends that medications
be chosen on the basis of side effects, tolerability, patient preference, and cost (APA,
2000b; Ellis & Smith, 2002). Antidepressant medications reconmiended for the
treatment of Depressive Disorders include selective serotonin reuptake inhibitors
(SSRIs; e.g. fluoxetine, sertraline, paroxetine), serotonin-noradrenalin reuptake
inhibitors (SNRIs; e.g. venlafaxine, nefazodone), tricyclic antidepressants (TCAs; e.g.
imipramine, nortriptyline, amitryptiline), and reversible monoamine oxidase inhibitors
(MAOIs; e.g. moclobemide).
Premature discontinuation of antidepressant medication can result in relapse in
up to 50% of patients (Angst, 1997; Hirshfield, 2001). Therefore, recommendations
have been made regarding the amount of time required to adequately treat symptoms
and reduce the risk of relapse. In reviews of clinical studies, the average length of
time considered appropriate for medication treatment to continue is 4 to 6 months
following remission (Angst; Keller & Boland, 1998). Remission has been defined as a
period, usually less than 6 months, during which an improvement in symptoms is
observed (Frank et al., 1991). Ellis and Smith (2002) state that medication should
continue for at least one year following an initial episode of depression, and that
treatment be extended to 2 years or more if there is a history of multiple episodes.
These guidelines have been supported by clinical trials which show antidepressant
medications effectively treat depression, with significant reductions observed in both
depressive symptoms and the risk of relapse when antidepressant medication is

maintained for at least 12 months (Keller et al, 1998; Kocsis et al., 1996). But despite
these guidelines, non-adherence to antidepressant medication remains a major barrier
to effective treatment of depressive disorders (Demyttenaere, 2001).

NON-ADHERENCE TO ANTIDEPRESSANT MEDICATION

The term 'adherence' is a relatively new term for describing medication-taking
behaviour. Traditionally, medication-taking behaviour has been described by the term
'compliance'. Compliance is defined as the extent to which a patient conforms to the
prescription of a physician, though the use of this term has been criticised as it
suggests that the patient is wrong and disobedient for not taking their medication as
prescribed (Aslani & du Pasquier, 2002). The term adherence is thought to overcome
this by implying greater patient involvement, empowerment, and choice in the
prescription process (Aslani & du Pasquier). Adherence and compliance are often
used interchangeably in the literature. The two terms are typically defined as 'the
degree to which a person adheres to the prescribed treatment regimen" (Maidment,
Livingston, & Katon, 2002, p. 752). Aslani and du Pasquier suggest that the definition
of non-adherence broadly means that a patient takes less than the prescribed dose by
missing or skipping doses. However, broader definitions can include taking too much
medication or taking medications in the wrong manner (e.g., saving up medications
and taking them all in the evening even though they were prescribed as three separate
doses through the day).
Rates of non-adherence among patients taking antidepressant medication is
high and variable. In a review by Cramer and Rosenheck (1998), estúnates of nonadherence rates among patients taking antidepressant medication averaged 35%,
ranging from 10% to 60% non-adherence. It is reported that approximately 25% of
primary care patients do not take all of their doses of antidepressant medication over a
2-week period (Aikens, Nease, Nau, Klinkman, & Schwenk, 2005). Within the first
month of treatment, between 28% and 35% of primary care patients stopped taking

'

3 0009 03441797 7

il

antidepressant medication (Lin et al., 1995; Simon, Von Korff, Wagner, & Barlow,
1993). It was also found that 29% of patients did not fill their initial prescription
(Simon et al.). After 3 months, 44% of patients were no longer taking their medication
(Lin et al.).
In another primary care study, 60% of patients were found to have stopped
taking antidepressant medication before completing the recommended 6 months of
treatment (Katon, Von Korff, Lin, Bush, & Ormel, 1992). Maidment et al. (2002)
found that approximately 19.4% of 67 older adults in primary care who had been
prescribed antidepressant medication were variable in the amount to which they
adhered to their medication, and a further 13.4% reported they never adhered to their
antidepressant medication.
The consequences of premature discontinuation of antidepressant medication
are generally negative. For example, Melfi et al. (1998) found a 77% increase in the
risk of recurrence of depression amongst patients who had prematurely discontinued
antidepressant medication, with one quarter of patients experiencing recurrence within
a 2-year period. Hirschfeld (2001) found that depression recurred in approximately
60% of cases within 12 months of an episode when antidepressant medication was not
provided. Of those treated with medication, 33% to 50% of patients relapsed after not
continuing to taking medication for a recommended period of 6 to 12 months. The
risk of relapse dropped to between 10% and 15% for patients who continued
antidepressant medication for the recommended period (Hirschfeld).
Failure to adhere to medication regimes has been associated not only with
increased psychopathology, but also increased negative psychosocial consequences
such as decreased work productivity and reduced quality of life (Keller & Boland,
1998).

Factors Influencing Medication Adherence
Reasons for non-adherence are multifactorial. However, a number of studies
have identified similar factors influencing adherence to antidepressant medication. In
particular, a review of the barriers to antidepressant medication adherence identified
four categories of influence: patient barriers, clinician barriers, clinical and policy
barriers, and minority population barriers (Unuetzer, Katon, Sullivan, & Miranda,
1999). Table 1 outlines the key factors influencing adherence to antidepressant
medication identified in the literature, listed as per the categories suggested by
Unuetzer et al.
Theoretical Models to Explain Adherence
Dunbar-Jacob (1993) notes in psychological research there are many models
of health behaviour that have been used in an attempt to understand adherence. Three
of the most widely used models are the Health Belief Model (Becker, 1974; Janz &
Becker, 1984; Janz, Champion, & Strecher, 2002; Rosenstock, 1974), the Theory of
Reasoned Action (Ajzen & Fishbein, 1980; Fishbein, 1967) / Theory of Planned
Behaviour (Ajzen, 1991), and the Common-Sense Model of Self-Regulation
(Leventhal, Brissette, & Leventhal, 2003; Leventhal, Leventhal, & Contrada, 1998).
The common element shared by these models is that they regard beliefs as playing a
major role in predicting health behaviour (Dunbar-Jacob). DiMatteo (1991) noted that
these theories do not completely explain health behaviour, but that they are useful as
models for understanding and predicting behaviour. These models are thought to be
highly comparable in their ability to facilitate understanding and prediction of health

Table 1
Barriers to Adherence to Antidepressant Medication

Barrier

Patient

Examples

Being poor or older^; lack of knowledge about treatment^"*^;
sensitivity to stigma^; fears of addiction^"^; being male^;
medical co morbidity^; concurrent medications^; cognitive
impairment (e.g., remembering to take medication)^; mobility
(e.g., obtaining prescriptions)^; symptoms of depression (e.g.
poor motivation)^; side effects'''^'®"®; feeling better'''®; adverse
life events^; cost of medication^'^; denial of illness'; beliefs
about medication (e.g. need for and harmfulnessy

Clinician

Lack of awareness of illness^; lack of skills^'^; lack of time to
spend with patients^; not following treatment guidelines'';
clinician-patient relationship'''^'®'^'; beliefs about non-adherent
patients (e.g. difficult, irresponsible)'''®

Clinical and policy

Geographic distance from health care^; concerns about
privacy^; confidentiality among rural communities^; limited
resources (e.g., funding for services)^

Minority populations

Low income^; being of an ethnic background^; cultural beliefs'^

® Unuetzer et al., 1999; Demyttenaere, 2001; Maidment et al., 2002; ^ Priest, Vize, Roberts, Roberts,
& Tylee, 1996;' Lin et al., 1995; ^ Masand, 2000; ® Demyttenaere, 1997; ^ Delgado, 2000;' Bollini,
Tibaldi, Testa, & Munizza, 2004; ^Aikens et al., 2005.

behaviour (Brannon & Feist, 2000; Weinstein, 1993), the Common-Sense Model
of Self-Regulation adding the benefit of considering beliefs related to medication use
which contribute to patient attitudes towards taking medication (Home, 2003).
Health Belief Model

The Health Belief Model (HBM) is one of the most well known psychological
models of health behaviour and it has been used in the study of adherence behaviour.
The model emphasizes the importance of attitudes and beliefs in decision-making.
The HBM proposes that engagement in behaviour (e.g. medication adherence) is
determined by weighing up the costs and the benefits of carrying out the behaviour
(Brannon & Feist, 2000; DiMatteo, 1991; Janz et al., 2002).
This cost-benefit analysis involves weighing four components (or
perceptions): perceived benefits, perceived susceptibility, perceived severity, and
perceived barriers (see Figure 1). According to the HBM, these four perceptions
influence whether an individual will engage in a particular behaviour. In an
application of the HBM to adherence behaviour Hughes, Hill, and Budd (1997) state
that an individual will comply with their prescribed medication regime based on the
perceptions regarding the four components of the model. For example, perceived
benefits relate to the benefits of treatment as perceived by the individual, or whether
the individual believes that medication will relieve them of symptoms. Perceived
susceptibility relates to how likely the individual believes they will continue to
experience symptoms without taking medication. Perceived severity refers to how
severe the individual perceives the illness is and/or will be if they do not take

medication. Perceived barriers refer to the negative consequences of taking
medication, such as side effects.
The HBM model has been used to understand and predict medication
adherence behaviour across a range of health conditions including depression (Adams
& Scott, 2000; Maidment et al., 2002), psychosis (Adams & Scott; Budd,

Individual perceptions

Likelihood of behaviour
change

Figure 1. Health Belief Model (adapted from Janz et al, 2002, p. 52).

Hughes, & Smith, 1996; Hughes et al., 1997), and HIV/AIDS (Malcolm, Ng, Rosen,
& Stone, 2003). Research data among patients with depressive disorders appears to
support the HBM model in that medication adherence is more likely among patients
whose perceived need for medication outweighs perceived harmfulness of medication
(Aikens et al., 2005). The model is useful for informing intervention programs that
aim to change health behaviour by providing an understanding of the patient's
decision making process which allows the intervention to be tailored to the identified
perceptions or HBM beliefs (DiMatteo, 1991; Janz et al., 2002).

Theory of Reasoned Action/Theory of Planned Behaviour

The Theory of Reasoned Action (TRA) and the Theory of Planned Behaviour
(TPB) provide a framework for identifying the reasons that determine one's
motivation or intention to perform a particular behaviour. According to the TRA,
behaviour is based on intentions to either engage or refrain from that behaviour
(Brannon & Feist, 2000; DiMatteo, 1991; Montano & Kasprzyk, 2002). The TRA was
later expanded to include the influence that perceived behavioural control has on
engaging in behaviour and was renamed the Theory of Planned Behaviour (TPB,
Ajzen, 1991). The components of the TPB are outlined in Figure 2.
Intentions are based on an individual's personal attitudes towards the
behaviour, the individual's perceptions of social pressure to engage or not engage in
the behaviour {subjective norm), and a person's perceived ability to carry out the
behaviour in spite of external or environmental barriers (perceived behavioural
control) (Montano & Kasprzyk).
Personal attitudes toward behaviour are based on the perceived outcomes or
consequences of the behaviour (behaviour beliefs), and the evaluation of whether the
outcomes are positive or negative. For example, if an individual believes that taking
medication will reduce their symptoms, and that a reduction in symptoms is a positive
outcome, then they will have a positive attitude toward taking medication. Subjective
norms are based on an individual's beliefs about whether their peer group or society
approve or disapprove of the behaviour (normative beliefs) and how much the
individual wishes to comply with these norms. For example, if an individual believes
that their peers will approve of them taking medication and the individual is

motivated to meet the expectations of their peers, then they will hold a subjective
norm that is likely to facilitate medication taking behaviour.
Perceived behavioural control is based on the individual's beliefs about
whether or not there are barriers to performing the behaviour {control beliefs) and the
extent to which the barriers will hinder the behaviour (actual behavioural control).
For example, if £in individual believes that medication is too expensive based on their
income, they are likely to have low perceived behavioural control. Taking all aspects
of the model together, if an individual holds a positive attitude towards medication,
has subjective norm beliefs that encourage medication taking, and believe tiiat they
have the ability to take medication without difficulty, then the individual is likely to
have high behavioural intention to take medication, which in turn will lead to the
individual taking the medication.

Actual
behavioural
control
Figure 2. Theory of Planned Behaviour (Ajzen & Fishbein, 2005).

This model enables identification of beliefs that affect behaviour.
Interventions designed to target individual beliefs about health behaviour can lead to
positive behaviour change (Montano & Kasprzyk, 2002). The model has been used to
predict adherence behaviour in areas such as medication treatment for bipolar
disorders (Cochran & Gitlin, 1988), condom use (Albarracin, Johnson, Fishbein, &
Muellerleile, 2001), and sunscreen use (Martin, Jacobsen, Lucas, Branch, & Ferron,
1999), highlighting its utility in adherence intervention development.
Common-Sense Model of Self-Regulation

As with the HBM and the TRA/TPB, The Common-Sense Model of SelfRegulation (CSM) looks at patients' attitudes about their illness and how they
influence intention and behaviour. In addition, the CSM also considers patient beliefs
that contribute to attitudes as a way of understanding behaviour (Home, 2003). Home
suggests that when health behaviour involves decisions about treatment (e.g., such as
taking medication) theoretical models should incorporate patient perceptions about
treatment as well as perceptions about their illness. For this reason it was proposed
that the CSM be extended to include a framework for understanding patients'
perceptions about treatment; specifically, perceived need for medication and
perceived concems about potential side effects (Home, 2003; Home & Weinman,
2002).
In Figure 3, the components of the CSM and addition of treatment perceptions
are outlined. The numbered pathways show how the model can be used to explain
medication taking behaviour. The model also highlights the importance of contextual

Contextual factors e.g., self-efficacy, social and cultural norms, personality

Perceptions of treatment e.g., needs and concerns

Health
Threat
e.g., symptoms
of information

Coping
procedure

Appraisal

r

Emotional
response to
illness

Coping
procedure

Appraisal

Emotional response to treatment e.g., worry, fear
Figure 3. Treatment Perceptions and the Common-Sense Model of Self-Regulation (from
Home, 2003, p. 148).
factors which influence a patient's perception of treatment and illness. The pathways
can be explained as follows: (1) the severity of a patient's symptoms or information a
patient may have about their illness {Health or Threat) will influence the patient's
perceived need for or concerns about treatment {Perceptions of treatment)', (2) the
processing of both the cognitive {Perceptions of treatment) and emotional aspects of
treatment {Emotional response to treatment) occurs in parallel; (3) the patient strives
for 'common-sense' coherence between their perceptions of illness and treatment,
weighing up the necessity of treating the illness {Illness representation) with the

concerns of treatment {Emotional response to illness) ; (4) patient perceptions of
illness and treatment, influence coping in the form of adherence {Coping procedure);
(5) the coping procedure (adherence or non-adherence) is evaluated in terms of it's
effectiveness for the patient {Appraisal) which either reinforces or changes the
patient's perceptions of treatment (see Home, 2003, p. 144-150 for further
explanation).
The CSM and the extended framework for understanding perceptions of
treatment, has been used to understand adherence behaviour in areas such as
preventative (e.g., asthma corticosteroid inhaler) medication management (Home &
Weinman, 2002) and shows preliminary empirical support for the model in explaining
adherence to highly active antiretroviral therapy (HAART) HIV treatment (Home,
Cooper, Fisher, & Buick, 2001).

REVIEW OF MEDICATION ADHERENCE INTERVENTIONS
Given the high rates of non-adherence to antidepressant medication and the
resulting negative consequences, it is not surprising that a number of interventions
have been developed over the years to enhance adherence (Katon et al, 1999, 2001;
Ludman et al., 2000; Mündt, Clarke, Burroughs, Brenneman, & Griest, 2001;
Vergouwen, Bakker, Burger, Verheij, & Koerselman, 2005). However, non-adherence
is not limited to depressive disorders, and a number of important adherence
interventions have been designed for other chronic health conditions. Key among
these has been Compliance Therapy (Kemp, Hayward, Applewhaite, Everitt, &
David, 1996). Compliance Therapy aimed to influence adherence behaviour among
patients with psychotic disorders through the use of motivational interviewing and
other cognitive behavioural techniques. It was one of the first attempts to
systematically evaluate a medication adherence intervention. In the Kemp et al. study,
47 patients with a psychotic illness were randomly assigned to an intervention
receiving 4 to 6 sessions of either Compliance Therapy or non-specific counselling.
Treatment sessions were delivered by highly trained clinicians (a psychiatrist and
clinical psychologist). Sessions were conducted twice a week and lasted between 20
to 60 minutes.
The content of Compliance Therapy consisted of a review and
conceptualisation of the patients' illness and medication adherence problems. Next,
specific discussions were conducted around issues such as side effects, the positive
and negative consequences of taking medication, and the stigma of taking medication.
Motivational interviewing techniques were conducted to explore ambivalence about
taking medication and cognitive therapy techniques were used to challenge beliefs

that impacted on adherence. Finally, self-efficacy was encouraged and the importance
of maintenance treatment highlighted. Non-specific counselling consisted of the
clinician listening to the patient's problems without discussion of treatment.
Patients were sampled from 2in inpatient facility over a period of 8 months. All
patients were diagnosed with a psychotic illness and all were taking antipsychotic
medication. Twenty-two patients received Compliance Therapy and 22 received
treatment as usual. All patients completed measures of symptom severity, insight,
attitudes towards medication, social functioning, and self-reported adherence preintervention, immediately after intervention, and 3 and 6 months post-intervention.
Results showed that patients who received Compliance Therapy had
significantly greater improvement than the non-specific supportive therapy group on
measures of insight, attitude towards medication and adherence to medication after
intervention and at 6 months post intervention (Kemp et al., 1996). However,
Compliance Therapy showed no significant improvement in symptom severity over
non-specific counselling. In a follow-up study, the effects found at 6 months post
intervention were maintained over an 18-month period (Kemp, Kirov, Everitt,
Hayward, & David, 1998). While Compliance Therapy improves adherence to
antipsychotic medication, it is limited by the need for highly trained clinicians to
deliver the intervention. Furthermore, Compliance Therapy focused on the
improvement of adherence to antipsychotic medication, not antidepressant
medication. There are specific factors which influence adherence to antidepressant
mediation (Unuetzer et al., 1999). Therefore it is unknown whether Compliance
Therapy is suitable for patients with depressive disorders who are non-adherent to
medication.

In an attempt to improve outcomes among primary care patients with
persistent depressive symptoms, Katon et al. (1999) evaluated a collaborative care
intervention using a psychiatrist and patients' primary care physician. Participants
were a group of 228 primary care patients, referred by their primary care physician
who had been prescribed antidepressant medication. Patients were randomly assigned
to the collaborative care intervention or usual care.
Collaborative care interventions were delivered by a psychiatrist and a
primary care physician. Patients met with the psychiatrist twice over a 4 week period.
The first session was a 50 minutes assessment session. The second session was a 25
minute follow-up session. The need for additional sessions was determined by patient
response to treatment. The initial session with the psychiatrist included a review of
illness, medical and social history, medication side effects and adherence. In addition,
the psychiatrist liaised closely with the patient's physician to assist in the alteration of
antidepressant dosage as required. Psychiatrists encouraged patients to engage in
psychotherapy if severe psychosocial stressors were present. Specific medication
adherence strategies used included education about antidepressant medication and
consultation with the psychiatrist. Usual care involved the patient receiving an
antidepressant medication prescription and visiting their physician two or three times
for follow-up over the intervention period.
Outcomes included medication adherence (based on self-report and data from
prescription refills), satisfaction with care, and depression outcomes. Measurement
occurred at 1, 3 and 6 months after patients were randomised to a treatment group.
The intervention group showed significantly greater self-reported adherence,
prescription refills, satisfaction with care, and depression outcomes, compared with
the treatment as usual group (Katon et al., 1999). However, the researchers caution (1)

that despite these effects, the collaborative nature of the intervention may be hard to
implement in areas where primary care and specialist services are not well integrated
and (2) patients included in the study were made available through referral and
diagnosis determined by their physician, reducing the generalisability of these results
to other patients with a diagnosable depressive disorder that may have been
misdiagnosed (Katon et al.). The second caution should also be considered in light of
the finding that primary care physician do not recognise approximately 50% of people
who have a diagnosable mental health condition (Hickie et al., 2001).
Ludman et al. (2000) aimed to enhance patients' use of antidepressant
medication and depression outcomes over 12 months through the delivery of an
intervention program that did not rely heavily on collaboration between practitioners
and patients in primary care. In this intervention, cognitive behavioural strategies
were used to address unrealistic beliefs about illness and treatment, and to highlight
the benefits of medication adherence. Education was provided about side effects and
early warning signs, to encourage help-seeking behaviour and self-management.
Motivational interviewing was used to overcome resistance to medication use and to
enhance motivation to engage in long-term adherence (e.g. 12 months). Follow-up by
phone and mail was used to encourage medication and adherence and monitor selfmanagement.
Participants were primary care patients who were identified as being at high
risk for relapse, based on their history. A total of 386 patients participated in the
study. Of these, 194 were randomly assigned to the intervention, while other
participants received usual treatment from their primary care provider. The
intervention was delivered over 12 months and consisted of two 30-minute videos and
a self-care book that participants received one week prior to face-to-face contact.

Face-to-face contact involved two 60-minute to 90-minute sessions, 2 to 4 weeks
apart, with a depression specialist. Face-to-face consultation included the
development of a relapse prevention plan, motivational interviewing, cognitive
behavioural therapy, and education about antidepressant medication and depression.
The depression specialist made contact (approximately seven contacts) with
participants over the remainder of the intervention time every 4 to 8 weeks by phone
or mail. This contact was intended to encourage medication adherence and selfmanagement. The depression specialists were a social worker, nurse, and a
psychologist, who had been trained over two half-days by a psychologist, psychiatrist,
and primary care physician. Depression specialists consulted with the psychiatrist
bimonthly over the course of the intervention to review patients' relapse prevention
plans and medication use.
Self-report of adherence and depressive symptoms was obtained preintervention and during phone contact with the depression specialist. The only formal
measure of assessment used was the Beck Depression Inventory (Beck, Ward,
Mendelson, Mock, & Erbaugh, 1961). Significant improvements in adherence and a
reduction in depressive symptoms were obtained for the intervention group, compared
with treatment as usual (Ludman et al., 2000). Ludman et al. concluded that this
intervention was effective in enhancing adherence to medication and improving
depression outcomes. This intervention required less direct patient contact from all
practitioners involved (e.g. only by the depression specialist). However, the use of
different practitioners in this study (e.g. the primary physician, psychiatrist and
depression specialist) still relied heavily on extensive collaboration and
communication among the highly trained providers. A final criticism is, like the
Katon et al. (1999) study, the generalisability of these results to individuals with

depressive disorders remains questionable given that diagnosis of depression was
established by patients' primary care practitioner.
Katon (2001) examined the effect of the intervention used by Ludman et al
(2000) on a more representative sample of high-risk primary care patients with
recurrent or chronic depression. With a focus on relapse prevention, Katon et al.
examined adherence to medication, depressive symptoms, and risk of recurrence over
a one-year period. Participants were randomly assigned to the intervention group or
treatment as usual. Usual care included a prescription for antidepressant medication
and between two to four follow-up visits with their physician. A total of 386 patients
sampled from primary care settings were included in the study after an assessment of
depression using the depression scales of the Structured Clinical Interview for the
Diagnostic and Statistical Manual for Mental Disorders, 3rd edition revised (DSMm-R, APA, 1987) (Williams et al., 1992) and Hopkins Symptom Checklist (Derogatis,
Rickels, Uhlenhuth, & Covi, 1974). Inclusion criteria were fewer than four symptoms
of MDD and a history of three or more Major Depressive Episodes, which the
researchers used to determine patients who had recovered but were at high-risk for
recurrence.
Adherence to medication, symptom severity, and recurrence was measured at
3, 6, 9, and 12 months. Over the year, patients in the relapse prevention group were
more likely to refill prescriptions for antidepressant medication and reported less
severe depressive symptoms than those receiving usual care (Katon et al., 2001).
However, no significant difference in reduction of the risk of recurrence was obtained
for the intervention group. Katon et al. concluded that a more intensive intervention is
required to reduce the risk of recurrence in patients with depression who have a highrisk of recurrence.

To provide comparison of the impact of an intensive (e.g. multi-strategy)
versus a non-intensive adherence intervention Vergouwen et al. (2005) randomly
assigned 211 primary care patients to either a non-intensive Follow-Up program {n =
110) or an intensive Depression Care program (n = 101) over 26 weeks. Follow-up
involved seven regular structured visits with a GP, with no specific strategies
implemented by the GP to enhance adherence. The Depression Care program
involved the same regular sessions with a GP and mail out of a newsletter to
participants, (prior to each session with a GP), which provided information about
medication, side effects, and the importance of adherence for up to 6 months. In the
Depression Care group, the GP was instructed to discuss the benefits of adherence
and to challenge perceived costs of adherence. The newsletters and sessions were
designed to specifically target adherence by providing education about antidepressant
medication and the importance of adherence, and by addressing participants' beliefs
about treatment through discussion with the GP.
Outcome measures included adherence (pill counts) and depressive symptom
outcomes, assessed during GP visits at weeks 2, 6, 10, 14, 18, 22, and 26. Risk of
relapse was not specifically measured. However, rates of remission were. Results
revealed that no significant differences in adherence rates, depression outcomes, or
rates of remission were found between the two interventions (Vergouwen et al.,
2005). Vergouwen et al. concluded that a less intensive, follow-up intervention
appears to be as effective as a more intensive intervention for adherence and
depression outcomes in primary care patients. However, the high frequency of visits
used in these interventions is noted as a potential barrier to feasible treatment delivery
in primary care (Vergouwen et al.).

In a novel attempt to eliminate the need for clinicians to deliver adherence
interventions, Mündt et al. (2001) examined the effect of an education only
intervention on antidepressant medication adherence. Participants were 246 patients
with MDD who had been prescribed antidepressant medication by their primary care
physician. Participants were randomly assigned to the intervention group or treatment
as usual. A total of 122 participants were included in the intervention group. The
intervention included time-phased mail outs of information about recovery from
depression and antidepressants directly to participants over a 7 month period. The
researchers hypothesised that the education material would provide patients with
sufficient support and information to encourage medication adherence, reduce
depressive symptoms, and reduce risk of relapse (Mündt et al.).
Participants completed measures of medication adherence (measured by
monitoring prescriptions filled), depressive symptoms, social and work adjustment,
and treatment satisfaction at 1, 3, and 7 months via telephone interviews. Results
revealed no significant differences between the intervention and treatment as usual
groups on measures of adherence to antidepressant medication, depression outcomes,
and risk of relapse. The findings suggest that education alone as an intervention is not
effective at enhancing adherence or reducing the risk of recurrence of depressive
symptoms. This study highlights the need for adherence interventions that do not rely
solely on education without clinical contact (Mündt et al., 2001) but instead
incorporate a range of strategies to target adherence (Kemp et al., 1996).
Overall, medication adherence interventions work to improve adherence to
antidepressant medication and reduce depression symptom severity over a 6 to 12
month period (Katon et al., 1999, 2001; Ludman et al., 2000; Vergouwen et al., 2005).
Katon et al. (2001) suggest that more intensive interventions are required to determine

how effective adherence interventions are at reducing the risk of recurrence. The
utility of many of these more complex or intensive interventions is often limited by
the need for highly trained clinicians (e.g., psychiatrists and physicians) to deliver the
interventions (Byrne, Deane, Coombs, & Lambert, 2004). The inclusion of such
highly trained clinicians in medication adherence interventions is not surprising, given
that the responsibility for enhancing medication adherence has traditionally been seen
as the domain of medical professionals such as primary care physicians, psychiatrists,
and even nurses (Coombs, Deane, Lambert, & Griffiths, 2003). It has been suggested
that given non-adherence is a common issue for primary care patients, the best way to
address non-adherence would be to educate and train a range of health professionals,
including allied health professionals, who provide services to primary care patients
(Haley et al., 1998; McDaniel, Belar, Schroeder, Hargrove, & Freeman, 2002).
Sawyer and Aroni (2003) suggest that adherence skills should be within the repertoire
of the broad cross section of health clinicians, not only clinicians specialising in the
pharmacological treatment of depressive disorders such as psychiatrists and
physicians. Furthermore, significant outcomes in adherence and depressive symptoms
can be achieved when such health professionals deliver adherence interventions
(Katon et al., 2001; Ludman et al., 2000)

EXPANDING THE SKILLS OF PRIMARY CARE CLINICIANS TO FACILITATE
MEDICATION ADHERENCE
Expanding the range of clinicians who provide adherence strategies to patients
in primary care is of particular importance within an Australian context. The capacity
to refer people with depression to psychological services has been expanded in
Australia under a raft of new government initiatives. Examples of these include the
Better Outcomes in Mental Health Care Program (2001 - 2005) and the Medicare
funded initiative Enhanced Primary Care. In November 2006 the Australian
Government announced funding of $538 million over 5 years to expand Medicare and
improve access to psychological services for individuals with a mental illness. This
enables patients to receive psychological services covered under Medicare. It is
important to note that while psychologists are one of the targeted professions to
provide these services, a range of allied health clinicians provide primary care
services to individuals with depressive disorders in Australia. One example of this
occurs in community health centres that employ a team of allied health clinicians to
provide primary care services. Within the centres, the term allied health clinician
often refers to psychologists, social workers, occupational therapists, and mental
health nurses.
There is considerable debate about whether psychologists should provide
medication-related services to patients (Walters, 2001). This is complicated by the
debate regarding whether psychologists should obtain prescription rights (Walters).
Overall, there is little data or commentary related to the role that allied health
clinicians should assume with regard to supporting medication adherence. Westerfelt
(2004) argues that allied health workers, such as social workers, should be encouraged

to facilitate patient adherence by encouraging patients to communicate with their
physician about their medication use and by providing patients with information about
their medication. Similarly, it has also been argued that psychologists are well
equipped to provide services that assist patients in their use of medication. In a
discussion of the collaboration that psychologists often have with their patients and
other health professionals, Weene (2002) states that psychologists already have many
skills that may be useful in facilitating medication adherence among their patients.
These include the ability to; deliver psychoeducation, develop a trusting therapeutic
relationship, monitor adherence, assess problems, and collaborate with other health
care providers (e.g., physicians).
There is limited data available on the practices of psychologists pertaining to
their involvement in the facilitation of adherence. Bascue and Zlotowski (1980) found
that 10% of psychologists in their US sample (N = 137) did not know if their patients
were taking medication, 23% stated they did not get involved in the facilitation of
medication use, and 6% believed that medication should not be used as a treatment for
depression. In a more recent survey, 96% of psychologists reported they were seeing
at least one patient who had been prescribed medication (VandenBos & Williams,
2000). Of these psychologists, 43% of the patients on their caseloads were receiving
psychotropic medication. While 99% of the psychologists indicated that they would
make a referral for medication evaluation or consultation, only 73% reported that they
do so routinely. Although 73% is a high rate of psychologists reporting they routinely
refer patients for medication evaluation or consultation, they reported doing so for
only up to 25% of their patients. Given that 43% of patients were receiving
medication, it does not appear that such referrals were routine practice for the
psychologists. Furthermore, 16% of psychologists said that they did not discuss

medication issues during therapy with any of their patients (VandenBos & Williams).
These findings are somewhat concerning as they suggest that many psychologists do
not routinely engage in strategies to facilitate patient adherence to medication and
some psychologists do not get involved in facilitating adherence at all.
Clinicians' Beliefs about Medications and their Role in Facilitating Medication
Adherence
In seeking to understand why clinicians don't use adherence strategies some
researchers have examined the role of the clinician's own beliefs upon their clinical
behaviour. Many researchers suggest that clinician beliefs about medication treatment
may influence the type of treatment the patient will receive, including whether they
receive help to use their medication more effectively (Byrne, Deane, & Coombs,
2005; Farris & Schopflocher, 1999; Ramstrom, Afandi, Elofsson, & Petersson, 2006;
Stern et al., 1999). Byrne et al. found that general beliefs about medications, as
measured by the Beliefs about Medicines Questionnaire (Home, Weinman, &
Hankins, 1999), predicted how effectively nurses indicated they were able to use
adherence strategies. Specifically they found that self-rated difficulty implementing
specific adherence strategies was influenced by both a lack of knowledge about
medication and negative beliefs about medication (Byrne et al.).
Ramstrom et al. (2006) found 51% of pharmacists agree that medications are
overused and that this belief may be a barrier to communication with patients.
Furthermore, pharmacists self-efficacy (self confidence) beliefs about their ability to
facilitate patient adherence has been found to be a direct predictor of pharmacist
behaviour, specifically that low confidence is a barrier to providing adequate

pharmaceutical care (Farris & Schopflocher, 1999). This is an important finding given
that self-efficacy, a person's beliefs about their ability and confidence to perform a
specific behaviour (Bandura, 1977), is reported to be a consistent predictor of
engagement in that behaviour (Bandura, 1977, 1997; Brannon & Feist, 2000).
Finally, Stem et al. (1999) found that 36% of psychologists and 54% of social
workers in their sample considered antidepressant medication to be somewhat
ineffective as a treatment option and they recommended that future research examine
a possible link between beliefs about medication and subsequent referral for an
appropriate medical review. Together these studies suggest clinicians' beliefs about
medication and their ability to facilitate adherence (including confidence, selfefficacy, and adequacy) may be related to the extent to which clinicians will engage in
behaviours that facilitate adherence (Byrne et al., 2005; Farris & Schopflocher, 1999;
Ramstrom et al., 2006).
Beliefs about antidepressant medication being helpful are associated with
knowledge of depression and professional experience in dealing with depressive
disorders (Jorm, Christensen, & Griffiths, 2005). This is demonstrated by the
significant difference in beliefs among different health professionals about whether
antidepressant medication is helpful for people with depressive disorders (Jorm et al.,
2005; Jorm, Korten, Jacomb, Rodgers, & Pollitt, 1997). For example, Jorm et al.
(1997) report that 89% of clinical psychologists identify antidepressant medications as
being helpful. In comparison, a survey of the Australian public revealed that only
25% of individuals (who were not clinically trained but who identified themselves as
having experience working with individuals with depressive disorders) reported
antidepressant medications as being helpful (Jorm et al., 2005). The significant
difference between beliefs about the effectiveness of antidepressant medication may

in part be associated with different levels of knowledge and experience (Jorm et aL,
2005).
In more recent studies it has been found that many health clinicians do not
appeeir to have received adequate training in adherence strategies and lack the
requisite skills and knowledge, or do not hold the necessary beliefs to support
adherence (Coombs et aL, 2003; Byrne et aL, 2004, 2005). This is despite evidence
that these elements can be enhanced (Byrne et aL, 2004; Gray, Wykes, & Goumay,
2003). As previously noted, it is imperative that a range of health clinicians develop
the appropriate knowledge and skills in this much needed area, given that there are a
diverse range of health professionals providing primary health care services to
individual with depressive disorders in Australia.
Effects of Medication Adherence Training on Clinicians' Knowledge, Skills, and
Beliefs
In the UK, Gray et al. (2003) evaluated the effectiveness of Medication
Management, a training program that enhances community mental health nurses'
(CMHN) clinical skills to a level necessary for the delivery of Compliance Therapy
(Kemp et aL, 1996). As previously reported. Compliance Therapy is an intervention
program designed to enhance medication adherence among individuals with psychotic
disorders (Kemp et aL). The Gray et al. (2003) study involved training 52 CMHNs
over 10 days in areas such as individualised assessment, cognitive therapy skills, and
psychopharmacology. Evaluation of the training revealed CMHNs achieved
significant increases in clinical skills and knowledge. In a follow-up study, the
patients of nurses who received training reported greater adherence to prescribed

medication and less psychopathology compared to patients receiving treatment as
usual (Gray, Wykes, Edmonds, Leese, & Goumay, 2004). The researchers concluded
that Medication Management training was an effective means of enhancing CMHNs
skills and knowledge to an adequate level for potential delivery of Compliance
Therapy (Gray et al., 2003) and that this training improved clinical outcomes for
patients with schizophrenia (Gray et al., 2004).
The research conducted by Gray et al. (2004) is promising for expanding the
skills of clinicians to facilitate adherence, but there are three issues that need to be
addressed to enhance the efficacy and feasibility of training; (1) clinician beliefs need
to be assessed and targeted during training, (2) a 10-day training program for
clinicians is not feasible within Australian primary care settings, and (3) future studies
need to be broadened to include a wider range of allied health clinicians treating
people with mental health issues in Australia, not just nurses who are often assumed
to have the main role in the facilitation of medication adherence (Coombs et al.,
2003).
Surguldaze, Timms, and David (2002) addressed two of these issues (i.e. the
length of the training program and lack of focus on clinician beliefs) by developing a
shorter, 2-day version of Compliance Therapy training that specifically aimed to
increase trainees' understanding of adherence issues, skills to engage with and
manage patients with a psychotic disorder, attitudes towards patients with psychosis
who are non-adherent, and beliefs about the facilitation of adherence. Participants
were 73 psychiatrists in training, 19 of whom received the modified Compliance
Training and 54 served as a control group.
Pre- and post-training measures comprised questions about the causes of nonadherence, consequences of non-adherence, rating of skills important for building a

collaborative relationship with and managing patients with a psychotic illness, beliefs
about the management of psychosis, and attitudes towards non-adherence. After
training, psychiatric trainees reported a significant increase in their ability to identify
the causes and consequences of non-adherence and confidence in their skills to
manage patients with psychosis (Surguldaze et al., 2002). This increase was
significantly higher than those reported in the control group. However, no significant
increases in ratings of skills important for building a collaborative relationship with
patients with a psychotic illness, beliefs about the management of psychosis, or
attitudes towards non-adherence were obtained over the course of training
(Surguldaze et al.). It is important that clinicians' hold the necessary beliefs to
facilitate medication adherence as such beliefs can influence whether or not clinicians
will engage in strategies to facilitate medication adherence (Byrne et al., 2005; Farris
& Schopflocher, 1999; Ramstrom et al., 2006; Stem et al., 1999).

MEDICATION ALLIANCE
In an effort to capture the essential ingredients of Medication Management
(Gray et al., 2003) and Compliance Therapy (Kemp et al., 1996) while addressing
their shortcomings, Byrne et al. (2004) developed Medication Alliance for delivery in
Australian primary care services. Medication Alliance is a training program designed
to enhance the skills, knowledge, and beliefs of clinicians working with individuals
who have been prescribed medication and who are non-adherent. In its original form
(Byrne et al.) it is a 3-day training program for mental health clinicians working with
individuals with psychosis who are non-adherent to medication.
The program comprises several features of previous medication adherence
programs (Gray et al., 2003; Kemp et al., 1996), as well as additional strategies
suggested as being effective in enhancing adherence, but which were lacking in
previous training programs. These core components include; developing a therapeutic
alliance, individualised assessment, cognitive interventions, motivational interviewing
and problem solving. It was modelled largely from Medication Management and was
developed in consultation with Medication Management researchers (Gray et al.). A
copy of the Medication Alliance program as used in Byrne et al. (2004) can be found
on the appended CD-ROM file Medication Alliance training program topics.
Medication Alliance Core Components
Therapeutic Alliance
Horvath (2000) notes that for any form of change to occur in therapy, a

positive therapeutic alliance is vital. A strong therapeutic alliance helps to develop
trust and creates an environment in which an individual can feel safe and secure
enough to explore behaviour change (Horvath). As conceptualised by Bordin (1979),
the therapeutic alliance describes the relationship between the therapist and patient,
comprising of the development of an emotional bond and the agreement of tasks and
goals in therapy. Bond is the emotional side of the alliance, comprising relational
qualities such as trust, respect, and caring. The agreement of tasks within therapy
involves a mutual understanding of issues related to the type of task, timing and
structure of activities. Agreement of goals emphasises the necessity of a mutual
agreement of the therapy goals including an agreement on the investment in and
achievement of the goals.
The importance of developing a strong therapeutic alliance is well established
given that regardless of other treatment variables, it is found to be a consistent
predictor of positive outcomes in therapy (Ellis & Smith, 2002; Howgego,
Yellowlees, Owen, Meldrum, & Dark, 2003; Martin, Garske, & Davis, 2000).
Similarly, in a number of studies, the therapeutic alliance has been found to predict
adherence to medication regimes. For example, therapeutic alliance was the most
consistent predictor of adherence to antipsychotic medication among outpatients with
psychotic disorders, compared with other variables thought to influence adherence
(Weiss, Smith, Hull, Piper, & Huppert, 2002). The importance of alliance in treatment
adherence is supported by numerous authors (Delgado, 2000; Demyttenaere, 1997;
Frank, 1997). However, there has been a lack of focus on developing a therapeutic
alliance in previous medication adherence intervention programs. In an attempt to
incorporate the development of a therapeutic alliance as part of training, Surguldaze et
al. (2002) measured the effects of Compliance Therapy on psychiatric trainees'

confidence in their skills to develop an alliance with their patient. No impact on
psychiatric trainees' confidence to build a therapeutic alliance was obtained over the
course of training.
Medication Alliance incorporates the importance of developing a strong
therapeutic alliance by focusing on the agreement of tasks and goals during therapy
(Bordin, 1979). This is achieved during Medication Alliance training in the following
ways (see Medication Alliance training with people who have depressive disorders:
Training manual file on the appended CD-ROM, p.68-84, p.99-113, pl59-161);
•

Normalising medication non-adherence

•

Developing an understanding of what non-adherence is

•

Developing an understanding of what some of the specific medication
adherence issues are for individuals with depressive disorders

•

Identifying the specific factors that influence adherence

•

Encouraging the sharing of information about medication and nonadherence between clinician and patient

•

Developing empathy among clinicians for non-adherence issues

•

Setting an agenda with the patient which involves an agreement
between clinician and patient about what therapy will focus on and
what each individuals roles will be

Individualised Assessment

There are many factors that can influence an individuals' adherence to
medication. Therefore, treatments need to be tailored to the individual's specific
adherence needs. Furthermore, individualised treatment is an excellent way to foster

alliance and helps to enhance adherence to medication (Marland & Cash, 2001). In
order for individualised treatment to occur, an individualised assessment needs to be
conducted to identify all the possible causal variables influencing medication nonadherence (Haynes & Williams, 2003). Once the causal variables are identified,
individualised treatment planning can begin.
One type of individualised assessment strategy is 2i functional analysis
(Haynes, Leisen, & Blaine, 1997; Haynes & WiUiams, 2003). Functional analysis
allows for the identification of the function of a specific behaviour (such as not taking
medication) by gathering information about antecedents and consequences of the
behaviour (Tustin, 1993). As standard treatments may not be effective for some
patients with multiple problem behaviours, the functional analysis enables important
causal variables of behaviour to be identified so the most effective treatment can be
administered (Haynes & Williams, 2003). A causal relationship between two
variables is said to occur when "(a) they co vary (i.e., when one changes, so does the
other), (b) the causal variable reliably precedes the dependent variable (i.e., the
problem behaviour), (c) there is a logical connection, (d) alternative explanations for
covariance can be excluded" (Haynes et al., 1997, pp. 334).
A functional analysis of behaviour is essential in the conceptualisation of
hypotheses regarding cause, maintenance and treatment (Truax, 2001). Conducting a
functional analysis to identify the cause of non-adherence allows treatment planning
to focus specifically on the cause for non-adherence. However, there is a lack of
research into medication adherence programs that emphasise the need for such an
individualised assessment. This is despite the fact that individualised assessment is
recommended as an essential part of providing treatment (Truax).

Medication Alliance uses individualised assessment to help clinicians identify
specific causes for medication non-adherence adherence. This is achieved during
Medication Alliance training in the following ways (see Medication Alliance training
with people who have depressive disorders: Training manual file on the appended
CD-ROM, p.l 14-122, p.164-185);
•

Finding out what the medication adherence problems are through the
use of an illness timeline (a structured way of reviewing with the
patient times when medication was adhered to and not adhered to and
identifying proximal factors that may have influenced adherence)

•

Using functional analysis and case formulation to determine the most
likely causal factors of medication adherence, given the information
collected in the illness timeline

Cognitive Therapy

Cognitive therapy (Beck, 1964; Beck, 1995) is a structured psychological
intervention used to identify and modify dysfunctional thoughts, beliefs and
behaviours of an individual so as to produce a change in emotions and behaviour. It is
goal orientated and problem focused. In its original form (Beck, 1964) cognitive
therapy was designed to treat depression. Over the years, cognitive therapy has been
modified and adapted for use with a range of psychopathology. However, the
underlying principle of cognitive therapy remains the same. That is, "distorted or
dysfunctional thinking (which influences the patient's mood and behaviour) is
common to all psychological disturbances" (Beck, 1995, pp. 1).

Dysfunctional thoughts and beliefs are first identified and then a series of
different strategies are used to modify these in order to facilitate guided discovery of
more helpful thoughts and beliefs to bring about emotional and behavioural change
(e.g. take medications) (Beck, 1995). This is achieved by using a range of strategies to
reduce the conviction with which a thought or belief is held by evaluating them, and
then replacing the thought or belief with a more helpful, realistic ones (Beck, 1995).
Modification of patient beliefs about taking medication is an important component in
Medication Alliance training given that these beliefs have been significantly
associated with medication adherence (Aikens et al., 2005; Home & Weinman, 1999).
Brown et al. (2005) identified specific beliefs that influence antidepressant
medication adherence among primary care patients by administering the Beliefs about
Medicines Questionnaire (Home et al., 1999) to a sample of 192 patients. The
findings showed that 51% of patients believe antidepressant medication is overused,
27% believe doctors place too much trust in medications, 23% believe most
medications are addictive, 49% are concerned about the long-term side effects of
medication, and 37% worry about becoming dependant on their medication.
Cognitive therapy has been used successfully to modify patient beliefs about
taking medication in previous medication adherence interventions (Gray et al., 2004;
Kemp et al., 1996). In the Gray et al. (2004) study, nurses who had been trained (see
Gray et al., 2003) in specific cognitive therapy interventions such as identifying
patient beliefs about medication and challenging these beliefs through guided
discovery, were more effective in improving patient attitudes towards antipsychotic
medication and medication adherence. Kemp et al. demonstrated that through the use
of cognitive strategies, patients with psychotic disorders showed significant increases
in their attitudes towards antipsychotic medication, insight into their illness, and

adherence to medication. These strategies used included (adapted from Kemp et al., p.
346);
Reviewing the patient's illness history
Conceptualising the problem of adherence
Discussion about symptoms and side effects of treatment
Processing the benefits and drawbacks of medication
Exploring the patient's ambivalence
Highlighting discrepancies between the patient's actions and beliefs
Focusing on adaptive behaviours
Encouraging self-efficacy
Discussing the value of staying well and thus the need for maintenance
of medication
During Medication Alliance training, cognitive therapy is used to challenge
and modify patient beliefs about medication and adherence issues in order to facilitate
prescribed adherence to antidepressant medication. Knowledge of specific
antidepressant medication beliefs such as those reported by Home et al. (1999) can be
used to specifically tailor cognitive therapy strategies. In addition to the strategies
used in the Kemp et al. (1996) study, the cognitive strategies used in Medication
Alliance training include (see Medication Alliance training with people who have
depressive disorders: Training manual file on the appended CD-ROM, p.202-218);
•

Discussing thoughts, feelings, and beliefs that concern patients about
their medication usage

•

Developing an understanding of the cognitive model and how
thoughts, feelings and behaviours interact

•

Developing clinician ability to identify thoughts and beliefs about
medication and medication adherence

•

Understanding and normalising distorted thinking styles

•

Increasing and assessing doubt about the validity of thoughts and
beliefs

•

Gathering evidence to challenge beliefs

•

Identifying alternative thoughts and beliefs that are more facilitative of
medication adherence

Motivational

Interviewing

Motivational interviewing is a directive yet patient-centred technique for
increasing problem recognition and enhancing motivation to change (Miller &
Rollnick, 1991, 2002). By using interviewing strategies such as reflective listening
and direct questions the clinician can help the patient to develop an awareness of the
discrepancies between their current problem behaviour (e.g. not taking medication)
and their values or goals (e.g. being well) (Burke, Arkowitz, & Menchola, 2003).
The goal of motivational interviewing is to enhance the patient's perspective
of the importance of changing their behaviour to reach a desired outcome (e.g.
adhering to medication to reduce symptoms and the risk of relapse). To do this, it is
important for the patient and not the clinician to develop reasons for change (Burke et
al., 2003; Miller & Rollnick, 1991). This goal is reached by the clinician utilising five
basic principles of motivational interviewing (1) expressing empathy, (2) developing
discrepancies, (3) avoiding argumentation, (4) rolling with resistance, and (5)
encouraging self-efficacy (Miller & Rollnick).

Motivational interviewing has been used extensively in adherence
interventions and is regarded as an effective strategy for enhancing adherence (Kemp
et al., 1996; Ludman et al., 2000; Rusch & Corrigan, 2002; Zygmunt, Olfson, Boyer,
& Mechanic, 2002), Kemp et al. found that patients with psychosis, who had received
Compliance Therapy, which has significant motivational interviewing components,
demonstrated more positive attitudes towards medication, enhanced insight into
illness, and increased adherence to antipsychotic medications than those treated with
non-specific counselling. Specific motivational interviewing strategies used in
Compliance Therapy included identifying the costs and benefits of taking medication
and exploring patients' ambivalence to take medication, and developing discrepancies
between their current medication taking behaviour and their beliefs. Similarly,
Ludman et al. used motivational interviewing strategies, such as rolling with
resistance, exploring ambivalence, and developing discrepancies, as a significant
component in their adherence intervention to significantly increase patients'
adherence to antidepressant medication.
Motivational interviewing is used in Medication Alliance training to help
patients reach a point where they can understand the importance of medication
adherence in reaching personally relevant goals. This is achieved during training in
the following ways (see Medication Alliance training with people who have
depressive disorders: Training manual file on the appended CD-ROM, p.85-98,
p. 186-201);
•

Understanding the patient's level of motivation to take medication
and/or resistance to medication adherence (including what is
resistance, how is it shown, and where does it come from)

Developing skills to discuss medication adherence with resistant or
unmotivated patients
Exploring and building patient importance and confidence in
medication adherence
Understanding when to roll with resistance and when to encourage
motivational change in order to preserve therapeutic alliance
Exploring ambivalence, weighing up the good and bad things about
medication adherence, and helping patients to 'tip the scales' towards
medication adherence behaviour

Problem Solving

Problem solving is a technique used to assist individuals in identifying
alternative ways of dealing with problems during everyday life (Chang & D'Zurilla,
1996). Chang and D'Zurilla's problem solving outcomes are achieved through the two
processes of problem orientation and problem solving proper. Problem orientation is
related to how an individual thinks or conceptualises their everyday life problems and
how they perceive their own problem-solving ability, while problem solving proper
refers to the process of identifying alternative solutions to problems in an attempt to
find a solution that is the most likely to lead to a desired outcome (Chang &
D'Zurilla). Problem solving proper is often used in medication adherence
interventions as a strategy to identify problems with taking medication and
developing solutions to overcome barriers (Kemp et al., 1996; Miklowitz, George,
Richards, Simoneau, & Suddath, 2003).

Providing patients with problem solving strategies to overcome adherence
issues has been noted as an important strategy in a review of effective adherence
intervention programs for people with schizophrenia (Zygmunt et al., 2002). In a
randomised study of outpatient management of bipolar disorder, patients who
received an intervention incorporating problem solving skills showed better
medication adherence over 2 years than patients receiving a less intensive, crisis
management intervention (Miklowitz et al., 2003). The specific problem solving
strategies used were identifying a problem specific to treatment management,
brainstorming solutions, evaluating the advantages and disadvantages of each
solution, and choosing a solution to implement (Miklowitz et al.).
Problem solving is used in Medication Alliance training to help patients
overcome practical problems that impede medication adherence. This is achieved
during training in the following ways (see Medication Alliance training with people
who have depressive disorders: Training manual file on the appended CD-ROM,
p.123-143, p.219-220);
•

Defining the problem; using the problems identified during
individualised assessment

•

Generating alternative solutions to the problem

•

Looking at the disadvantages and advantages of each solution and
weighing up the alternatives

•

Encouraging the patient to choose the alternative that best suits them

•

Helping patients to make detailed plans of how to execute the solution

•

Encouraging patients to implement and evaluate the success of the
alternative solution through the use of systematic homework

Clinician Outcomes from the Medication Alliance Training Program
Byrne et al. (2004) delivered the program to 23 mental health workers in
Tasmania who were working with individuals with psychosis. The sample comprised
19 mental health nurses, 2 psychologists, 2 social workers, and 1 unreported
professional designation. Training included both didactic and interactive teaching
techniques, with time allowed for skill practice and role-plays. Measures taken preand post-training were used to assess changes in skills, knowledge, and beliefs over
the course of training. A number of measures were developed in order to assess
training outcomes. All measures were pencil-and-paper measures with the exception
of the Cognitive Therapy Scale for Psychosis, which was videotaped and blind-rated.
The Medication Alliance Cognitive Therapy Scale for Psychosis (based on the
Cognitive Therapy Scale for Psychosis^ Haddock et al., 2001) was developed to assess
video-taped segments of participants' demonstrating skills in delivering a range of
Medication Alliance strategies including agenda setting, problem solving, cognitive
challenging of medication beliefs, motivational interviewing, and homework.
The Functional Analytic Case Formulation was developed to measure how
effectively participants could identify causal variables of non-adherence. The measure
included a vignette which described a patient who was non-adherent to antipsychotic
medication. Imbedded in the vignette were a number of causal variable for nonadherence that participants had to identify.
Changes in knowledge were assessed using the Medication Alliance Clinician
Knowledge Questionnaire. This is a 15-item multiple-choice questionnaire asking
participants about the ways in which medication adherence can be influenced
(through the use of Medication Alliance strategies).

The Medication Alliance Beliefs Questionnaire (MABQ) was used to assess
participants beliefs related to working with individuals who are non-adherent to
medication. Twenty-two items are rated on a 5-point Likert scale (1 = Strongly
Disagree" to 5 = Strongly Agree"), with higher responses indicating more positive
beliefs. Subscales of the MABQ included Adequacy, Legitimacy, Motivation, Work
Satisfaction, and Self Esteem.
The Elsom Therapeutic Optimism Scale (Elsom, 2002) was used to measure
participants' optimism about medication as an effective treatment option for patients.
Comparison of pre- and post-training outcomes showed that Medication
Alliance training significantly increased clinician knowledge about medication
adherence issues and knowledge of the strategies that can be used to facilitate
adherence. In addition, skills to effectively enhance medication adherence, and
specific beliefs about clinicians' adequacy, work satisfaction, and optimism about
working with individuals who are non-adherent were all improved (Byrne et al.,
2004). The relative brevity of Medication Alliance in comparison to other medication
adherence interventions (Gray et al., 2003) also increased it's feasibility for delivery
within Australian primary care settings.
However, the intervention focused only on clinicians who identified
themselves as having a legitimate role in facilitating adherence (Coombs et al., 2003).
A weakness in the Byrne et al., (2004) study is that it failed to account for clinicians
for whom facilitating adherence is not a typical role. Addressing the knowledge,
skills, and beliefs of a range of mental health clinicians is important, given that many
clinicians (e.g. allied health clinicians) are working with individuals under primary
health care initiatives in Australia (e.g. Better Outcomes in Mental Health Care and
Enhanced Primary Care) who may be nonadherent. Furthermore, this training

focused on enhancing clinicians' knowledge, skills, and beliefs, related to facilitating
adherence among patients with psychosis; it is not known if this training program is
effective at enhancing the knowledge, skills, and beliefs of allied health clinicians
working with patients with depressive disorders who are non-adherent to
antidepressant medication.

The Present Study

Patients with depressive disorders are commonly referred by primary care
physicians to specialist allied health services, such as psychological services. While
psychologists provide the majority of these services, a range of allied health clinicians
provide primary care services to individuals with depressive disorders in Australia. As
a result, allied health care providers are often in a position to support or facilitate the
adherence of patients to antidepressant medication in primary care environments.
However, there is a dearth of information about the current medication adherence
practices of allied health clinicians in Australia who work with primary care patients
with depressive disorders. Specifically, it is unclear whether allied health
professionals view facilitation of medication adherence as part of their role.
Furthermore, it is unclear whether a broader range of clinicians, such as allied health
clinicians, can be trained in medication adherence interventions, given that previous
interventions have generally required highly trained clinicians to deliver such
programs (Kemp et al., 1996) or have only trained with clinicians who are perceived
as having a role in facilitating adherence (Byrne et al., 2004; Gray et al., 2003).
This research sought to identify the extent to which allied health clinicians
believe helping patients adhere to their medication is a role in which they should

engage and the extent to which they use specific adherence strategies (Study 1).
Furthermore, this study examined the impact of a modified Medication AUiance
training program on clinicians' knowledge, skills, and beliefs related to facilitating
medication adherence among individuals with depressive disorders (Study 2).

STUDY 1:
PRIMARY CARE ALLIED HEALTH CLINICIANS' VIEWS OF THEIR ROLES
IN FACILITATING ANTIDEPRESSANT MEDICATION ADHERENCE AND
PREDICTORS OF ADHERENCE STRATEGY USE
It was hypothesised that beliefs about medication, beliefs about allied health
professionals' role in facilitating adherence, adequacy (self-efficacy), and previous
training in specific medication adherence strategies would be related to the extent to
which allied health clinicians working with primary care patients report using specific
medication adherence strategies. It is expected that previous training, more positive
beliefs about medication, beliefs that allied health clinicians have a role in facilitating
adherence, and higher adequacy, will be associated with greater self-reported use of
specific strategies to enhance adherence. The degree to which these variables predict
self-reported use of specific strategies was also explored.
Method
Participants and Procedure
Participants were 72 allied health clinicians (i.e., psychologists, social
workers, occupational therapists) working with primary care patients. To ensure
participants were delivering services to primary care patients, specific questions about
the context of their clinical work were asked. Participants who satisfied this criterion
were those who indicated they were (a) working in a primary care setting such as a
Division of General Practice or community health centres, and/or (b) providing

services under a primary care program (e.g., Better Outcomes in Mental Health Care
and/or Enhanced Primary Care). A convenience sample of participants was accessed
via mail or face-to-face delivery of surveys. Psychologists working in private practice
in the South Eastern Sydney and Illawarra areas were accessed via mail from
addresses listed in the Yellow Pages. Psychologists on a nation-wide mailing list held
by the Australian Psychological Society were also accessed via mail. Individuals on
this list had previously consented to being contacted for research distributed by the
Australian Psychological Society. Primary care agencies in the South Eastern Sydney
and Illawarra Area Health Service were contacted to arrange a time to visit and leave
surveys for allied health clinicians to complete. In return for involvement in the study,
participants were offered the opportunity to enter a draw for a book voucher. Separate
reply paid envelopes were provided to return their book voucher entries to ensure that
surveys remained anonymous.
A total of 212 surveys were distributed; 101 were mailed out following
identification in the Yellow Pages, 61 were mailed out via the APS mailing list, and
50 were delivered directly to primary care agencies. Eighty-eight surveys were
returned, giving a response rate of 41.5%. Eighteen surveys were excluded from the
analysis because 14 participants did not indicate they were currently working within a
primary care context, and 4 participants indicated they were non-allied health
professionals (e.g. physicians or nurses). Thus, the following analyses were based on
72 participants who met entry criteria. Most participants were female (75%, n = 54).
The mean age of participants was 42.6 years (range 22 to 69 years). Participants
included 54 psychologists (75%), 12 social workers (16.7%), and 6 occupational
therapists (8.3%). The average length of time that participants had worked in their
profession was 11.4 years (range 0 to 37 years). The majority of participants (76.4%,

n = 55) worked 30 or more hours per week in their profession. Participants were
mostly from NSW [(90.3%, n = 65, with the remainder from VIC (2.8%), QLD
(2.8%), WA (1.4%), and ACT (1.4%)].
Thiry-one participants (43.1%) identified themselves as working with patients
through the Better Outcomes in Mental Health Care program, while 34 (47.2%)
reported that they were working with patients through the Enhanced Primary Care
initiative. Of these, 16 participants (22.2%) identified themselves as working with
patients through both the Better Outcomes in Mental Health Care program and
Enhanced Primary Care initiative. Cognitive behavioural therapy was reported as a
model of therapy used by 27 participants (37.5%), while 27 participants (37.5%)
reported using eclectic or integrated models. Other models of therapy reportedly used
were existential psychology, rehabilitation models and personal construct
psychotherapy (13.9%). Eight participants (11.1%) did not report the type of therapy
model they used. Places of work were reported as private practice (44.5%),
community health centres (37.5%), community mental health centres (23.6%),
hospitals (4.2%), and 'other' (2.8%). There was some overlap of places of work, with
13.9% of participants identifying themselves as working in both community based
and private practices. There was missing data for the place of work for one participant
(1.4%). The average number of patients on participants' active case loads was 28
(range 1 to 100).
Materials
See Appendix A for a copy of the survey used in this study. The survey had
four sections: (Section A) demographic and background details, (Section B) general

beliefs about medication, (Section C) general beliefs about adequacy to facilitate
adherence, and (Section D) specific beliefs about facilitating adherence among
individuals with depressive disorders who are non-adherent to antidepressant
medication.
Section B included the 8-item General scale of the Beliefs about Medicines
Questionnaire (Home et al., 1999: BMQ). Items are rated on a 5-point Likert scale (1
= ''Strongly Disagree'', 2 = ''Disagree'', 3 = "Uncertain", 4 = "Agree" to 5 =
"Strongly Agree"), with higher scores indicating more negative beliefs. The items
provide two subscales. Overuse and Harm. The Overuse subscale consists of four
items (score range 4 to 20) to examine the extent to which the clinician believes
doctors overuse medications {"Doctors use too many medications", "Natural remedies
are safer than medications", "Doctors place too much trust on medications ", and "If
doctors had more time with patients they would prescribe fewer medications"). The
Harm subscale also consists of four items (score range 4 to 20) to identify the extent
that the clinician believes medications are harmful or poisonous {"People who take
medications should stop their treatment for a while every now and again", "Most
medications are addictive", "Medications do more harm than good', and "All
medications are poisons").
Home et al. (1999) found satisfactory internal consistency (Cronbach alpha
coefficients) for the Overuse subscale in samples of general medical inpatients {n =
90, a = .60) asthmatic patients {n = 78, a = .74), diabetic {n = 99, a = .80), renal {n =
47, a = .77), cardiac (w = 116, a = .74), and psychiatric patients {n = 89, a = .73).
Mixed intemal consistency was found for the Harm subscale among diabetic (a =
.66), renal (a = .83), psychiatric (a = .70), general medical (a = .51), asthmatic
patients (a = .47), and cardiac patients (a = .51). Intemal consistency was improved in

later research with 600 undergraduate students, by assigning the item ''Natural
remedies are safer than medications'" to the Harm subscale and excluding the item
"A// medications are poisons'" (Home et al., 2004). Alpha values for this modified
version were a = .72 and a = .62 for the Overuse and Harm subscales respectively.
Ramstrom et al. (2006) also used this modification in their sample of 141 pharmacy
patients and 136 pharmaceutical specialists, obtaining alpha values of a = .65 and a =
.70 for the Overuse and Harm subscales respectively.
Using the original 4-item Overuse and 4-item Harm subscales (Home et al.,
1999), sufficient intemal consistency for research purposes was obtained in the
present study; a = .66 (Overuse) and a = .67 (Harm). When the changes used by
Home et al. and Ramstrom et al. (2006) were applied in the present study, intemal
consistency was not significantly improved; a = .70 (Overuse) and a = .63 (Harm),
Therefore, the original 4-item Overuse and 4-item Harm subscales (Home et al.) were
retained. Taking the Overuse and Harm subscales as a total scale revealed higher
intemal consistency (a = .76). The Overuse and Harm subscale were used initially for
detailed analyses. The total scale was used for correlation and regression analyses.
Test-retest correlations of the Overuse and Harm scales have been reported at .60 and
.78 respectively (Home et al). Home et al. report that both subscales distinguish
between the beliefs of patients attending community pharmacies and those attending
non-medical clinics. Correlation between the subscales was reported at .40 (Home et
al.).
Section C included the 6-item Adequacy subscale from the 22-item Medication
Alliance Beliefs Questionnaire (MABQ). The MABQ explores clinician beliefs about
working with individuals who are non-adherent to medication (Byrne et al., 2004).
The questionnaire was originally adapted from ih& Alcohol and Alcohol Problems

Perception Questionnaire (Gorman & Cartwright, 1991) to assess clinician attitudes
to working with alcohol problems. Similar adaptations of the measure have been used
to assess clinician beliefs about working with individuals with psychosis (McLeod,
Deane, & Hogbin, 2002). The main modification of the questionnaire involved
replacing words related to ''drinking or alcohol use'' with ''medication adherence
issues'' (Byrne et al.).
Items are rated on a 5-point Likert scale (1 = "Strongly Disagree", 2 =
"Disagree", 3 = "Uncertain", 4 = "Agree" to 5 = "Strongly Agree"), with higher
responses indicating more positive beliefs. The Adequacy subscale total score ranges
from 6 to 30 and reflects how effectively the clinician believes they are able to help
individuals with medication adherence issues based on their knowledge and skill (e.g.,
"Ifeel that I can appropriately advise people about the use of their medications").
Cronbach alpha for the Adequacy scale has been reported at a = .83 in a sample of
292 mental health clinicians (Byrne, Deane & Caputi, 2006). In a previous version of
the Adequacy scale, Cronbach alpha was reported at .77 in a sample of 77 mental
health clinicians (McLeod et al., 2002). In the present study Cronbach alpha was a =
.87.
Section D contained items specific to working with individuals with
depressive disorders who are taking antidepressant medication. Items were generated
by the researchers for the purposes of this study. Participants were asked to report the
number of patients with depressive disorders on their caseload who are non-adherent
to prescribed antidepressant medication. They were then asked to rate the question
"How true is it that patients who are non-adherent to antidepressant medication
occupy more ofyour time than those who are adherent to antidepressant

medication?''. This was rated on a 10-point Likert scale (1 = ''Not At All True''
through to 10 = ''Completely True").
The researchers developed a 3-item Effectiveness scale to assess participants'
beliefs about how effective antidepressant medication is as a treatment for depressive
disorders (e.g., "Antidepressant medication is an effective treatment for depressive
disorders"). Ratings were provided on a 5-point Likert scale (1 = "Strongly Disagree"
to 5 = "Strongly Agree"). The total score range for the Effectiveness scale was 3 to 15,
with higher scores indicating more positive beliefs about medication being an
effective treatment for depressive disorders. In the present study Cronbach alpha was
a = .69. A 2-item Role scale was developed to assess whether participants believe that
facilitating their patients' use of antidepressant medication is an appropriate
professional activity for them or not (e.g., "Helping patients adhere to antidepressant
medication is an appropriate professional activity for me"). Ratings were provided on
a 5-point Likert scale (1 = "Strongly Disagree" to 5 = "Strongly Agree"). The total
score range for the Role scale was 2 to 10, with higher scores indicating more positive
beliefs about helping with medication adherence being an appropriate professional
activity. In the present study Cronbach alpha was a = .88.
An 11-item Strategy Use scale was developed by the researchers from
previously research (see Byrne et al., 2005) to gauge the extent to which clinicians
reportedly used a variety of different strategies to help patients with their use of
medication (e.g., "I ask my patients to monitor their medication adherence", "I
encourage my patients to speak to their physician about medication adherence"). The
11 items on the Strategy Use scale were rated on a 5-point Likert scale (1 = "Not At
All", 2 = "A Little Bif, 3 = "Sometimes", 4 = "Often", to 5 = "Almost Always"). The
total score range for the Strategy Use scale was 11 to 55, with higher scores indicating

greater reported use of specific strategies to help with patient adherence. In the
present study Cronbach alpha was a = .89.
Finally, participants were asked if they had received any specific training on
how to enhance medication adherence, and if so, to provide details of the training (e.g.
number of hours of training, format of training).

Results

Statistical analyses were performed using the Statistical Package for the
Social Sciences (SPSS) for Windows (v. 15.0) (SPSS Inc., 2006). Participants reported
that an average of 45.7% (range 4% to 95%) of the patients on their caseload had a
depressive disorder. Of these patients, 63.9% (range 3% to 100%) had been
prescribed antidepressant medication, and of these 26.7% (range 0% to 80%) were
non-adherent to prescribed antidepressant medication. On a scale assessing whether
patients who are non-adherent to antidepressant medication occupy more time than
those who are adherent, participants reported an average of 4.8 (where 1 = ''Not At All
True'' to 10 = ''Completely True''). Approximately 40% of these participants reported
a score of 6 or greater.
The majority of participants (63.9%, n = 46) reported that they have not
received any specific training on how to enhance medication adherence. Of the 26
participants (36.1%) who reported they had received training, the majority (61.5%, n
= 16) received 8 hours or less of training. The range of training varied widely between
2 hours to 720 hours of training delivered in the format of workshops, reading, and
experience gained "on the job".

Table 2
Means (M), Standard Deviations (SD,) and Ranges for the Overuse,
Harm, Adequacy, Effectiveness, Role and Strategy Use Scales (N = 72)

M

SD

Range

Overuse

12.29

2.92

4 - 20

Harm

7.49

2.28

4 - 20

Adequacy

21.76

4.15

6 - 30

Effectiveness

10.86

1.67

5 - 15

Role

7.67

1.82

2 - 10

Strategy Use

38.90

8.40

11--55

Scales

Table 2 outlines the means, standard deviations, and ranges of the variables
used in the analyses (e.g.. Overuse, Harm, Adequacy, Effectiveness, Role, and
Strategy Use scales). Higher scores on the Overuse and Harm subscales indicate more
negative beliefs about the overuse and harmfulness of antidepressant medication,
respectively. Higher scores of the Adequacy subscale indicate more positive beliefs
about adequacy to help individuals with medication adherence issues. Higher scores
of the Effectiveness scale indicate more positive beliefs about the effectiveness of
antidepressant medication as a treatment for depressive disorders. Higher scores on
the Role scale indicate more positive beliefs about facilitating medication adherence
being an appropriate professional activity. Higher scores on the Strategy Use scale
indicate greater reported use of specific adherence strategies to help with patient
adherence.

Table 3
Percentage of Responses for Items in the Overuse and Harm Subscales of the BMQ
(N=72)

Subscales and items

Disagree/
Strongly
Disagree Uncertain

Agree/
Strongly
Agree

Overuse
"Doctors use too many medications"

26.8

18.3

54.9

"Natural remedies are safer than
medications"

65.3

27.8

6.9

"Doctors place too much trust on
medications"

21.1

15.5

63.4

"If doctors had more time with patients
they would prescribe fewer medications"

19.7

28.2

52.1

"People who take medications should
stop their treatment for a while every now
and then"

66.2

25.3

8.5

"Most medications are addictive"

85.9

11.3

2.8

"Medications do more harm than good"

84.5

12.7

2.8

"All medications are poisons"

88.9

6.9

4.2

Harm

Note. On a scale of 1 - 5, "'Disagree!Strongly Disagree" = 1 and 2, respectively; '"Uncertain" = 3;
"'Agree!Strongly Agree" - 4 and 5, respectively.

Table 3 outlines participants' responses for both the Overuse and Harm
subscales of the BMQ. Response ratings presented in Table 3 were organised into
three categories for descriptive purposes; those disagreeing {''Disagree" and ''Strongly

Disagree''), those rating ''Uncertain", and those agreeing CAgree'' and ''Strongly
Agree"). Overall, most participants agreed that medications are overused and
disagreed that medications are harmful. Almost 50% of participants did not agree or
were uncertain that doctors would prescribe less medication if they had more time
with patients. Over 90% of participants disagreed with or were uncertain about the
statement "Natural remedies are safer than medications". One third of participants
were uncertain or agreed that people should stop their treatment for a while every now
and then.
The response ratings for the Adequacy subscale of the MABQ are reported in
Table 4. Response ratings presented in Table 4 were organised into three categories
for descriptive purposes; those disagreeing {"Disagree" and "Strongly Disagree"),
those rating "Uncertain", and those agreeing {"Agree" and "Strongly Agree").
Overall, the majority of participants believed that they could adequately facilitate
medication adherence. However, approximately 50% of participants disagreed or
were uncertain that they could appropriately advise patients about their medication
use. Almost 50% did not agree that they knew enough about the risk factors for
developing medication adherence problems. Over 30% of participants reported that
they were not satisfied with the way they work with people with medication
adherence issues.
Table 5 outlines the response rates for the Effectiveness and Role scales. There
was missing data for two participants for the Effectiveness scale. The missing data
was replaced with item means of the total remaining sample of participants
(Tabachnick & Fidell, 2001). Response ratings presented in Table 5 were organised
into three categories for descriptive purposes; those disagreeing {"Disagree" and
"Strongly Disagree"), those rating "Uncertain", and those agreeing {"Agree" and

Table 4
Percentage of Responses for the Items in the Adequacy Subscale of the MABQ
(N=72)

Item

Disagree/
Agree/
Strongly
Strongly
Disagree Uncertain Agree

"I feel I know enough about the reasons why
people don't use medications"

12.5

11.1

76.4

"I feel I know how to counsel people who
have medication adherence issues over the
long term"

11.1

15.3

73.6

"I feel that I can appropriately advise people
about the use of their medications"

31.0

18.3

50.7

"I feel that I have a working knowledge of
medication adherence issues"

8.4

8.5

83.1

"On the whole I am satisfied with the way I
work with people who have medication
adherence issues"

8.3

23.6

68.1

"I feel I know enough about the factors
which put people at risk of developing
problems with the use of their medications"

12.7

35.2

52.1

Note. On a scale of 1 - 5, ''Disagree/Strongly Disagree" = 1 or 2, respectively; ''Uncertain" = 3;
"Agree!Strongly Agree" = 4 or 5, respectively.

''Strongly Agree"). Overall, participants agreed that antidepressant medication is an
effective treatment for depressive disorders. However, almost 75% did not agree that
depressed patients taking antidepressant medication will get better. While most
participants indicated that facilitating adherence is an appropriate professional activity
for them to engage in, 30% of participants did not agree or were uncertain.

Table 5
Percentage of Responses for Items in the Effectiveness and Role Scales (N = 72)

Scale and item

Disagree/
Strongly
Disagree Uncertain

Agree/
Strongly
Agree

Effectiveness
"Antidepressant medication is an
effective treatment for depressive
disorders"

8.6

17.1

74.3

"Antidepressant medication helps to
reduce the symptoms of depressive
disorders"

0.0

11.4

88.6

"Depressed patients who take
antidepressant medication will get better"

21.4

52.9

25.7

"Helping patients adhere to
antidepressant medication is an
appropriate professional activity for me"

12.7

16.9

70.4

"It is appropriate for clinicians without
medical training to assist patients with
medication adherence"

7.0

15.3

77.9

Role

Note. On a scale of 1 - 5, "Disagree/Strongly Disagree" = 1 or 2, respectively; "Uncertain" - 3;
"Agree!Strongly Agree" = 4 or 5, respectively.

Table 6 outlines the response rates for the Strategy Use scale. Response
ratings presented in Table 6 were organised into three categories for descriptive
purposes; those reporting they do not regularly use adherence strategies C^otAtAir
and "A Little''), those reporting they ''Sometimes'' use adherence strategies, and those
reporting they regularly use adherence strategies COften" and ''Almost Always"). The

Table 6
Percentage of Responses for the Strategy Use Scale Items (N= 72)

Items

Not At
All/
A Little Sometimes

Often/
Almost
Always

"I do not get involved with my patient's
medication adherence"

22.3

31.9

45.8

"I use specific interventions to enhance
medication adherence"

30.6

33.3

36.1

"I consult with a physician about my
patient's medication adherence"

23.6

27.8

48.6

"I discuss medication adherence issues with
my patients"

8.3

20.8

70.9

"I enquire about medication side effects
with my patients"

2.8

8.3

88.9

"I ask my patients to monitor their
medication adherence"

26.4

27.7

45.9

"I provide patients with information about
medication"

33.3

20.9

45.8

"I assess the possible causes of my patient's
medication non-adherence"

20.9

13.8

65.3

"I provide motivational strategies to help
my patients with adherence to medication"

26.4

22.2

51.4

"I encourage my patients to speak to their
physician about medication adherence"

2.8

8.3

88.9

"I use problem solving strategies to
overcome medication non-adherence"

22.2

30.5

47.3

Note. On a scale of 1 - 5, ''Not At All!A Little" = 1 or 2, respectively; ''Sometimes" - 3; "Often/Almost
Always" = 4 or 5, respectively.

most common strategies reported as being used regularly by participants to facilitate
medication adherence include discussing adherence issues with patients, enquiring
about side effects, assessing the possible causes of non-adherence, and encouraging
patients to speak to their physician about medication adherence. Only 50% of
participants reported that they regularly use motivational interviewing strategies to
facilitate adherence. Approximately 50% of participants report that they do not
regularly (as indicated by a response of''Not At AW\ "A Little'' and ''Sometimes'')
provide information about antidepressant medication, use problem solving strategies
to overcome adherence problems, or ask their patients to monitor their adherence.
Impact of Previous Training on Beliefs and Strategy Use
A series of between group i-tests were used to determine if previous training
had any impact on beliefs about medication (taking the Overuse and Harm subscales
as a total scale; Overuse+Harm), Adequacy, Effectiveness, Role, and Strategy Use
scales. The means and standard deviations of these variables for participants who had
received prior training in medication adherence strategies compared with those who
had not are reported in Table 7. All assumptions for conducting i-tests were met. The
results of the between group i-tests are shown in Table 7.
A total of 63.9% of participants reported that they had not received prior
training in medication adherence strategies and 36.1% reported that they had. The ttest results revealed that participants who had received prior training had significantly
(a) lower levels of beliefs that medications in general were overuse and harmful, (b)
more positive beliefs about adequacy to facilitate adherence, (c) more positive beliefs
about the effectiveness of antidepressant medication as a treatment for depressive

Table 7
Means (M), Standard Deviations (SD) and t-Test Statistics (t)for the Overuse+Harm,
Adequacy, Effectiveness, Role, and Strategy Use Scales for Participants Who Had
Received Prior Training Compared to Those Who Had Not (N =72)

Prior training
(n = 26)

No prior
training
in = 46)

Scales
M

SD

M

SD

t

P

Overuse+Harm

8.87

2.30

10.47

2.11

2.92

.003**

Adequacy

23.31

3.60

20.89

4.23

-2.57

007**

Effectiveness

11.37

1.58

10.57

1.63

-2.06

.022*

Role

8.54

1.30

7,17

1.90

-3.60

.001**

42.35

6.79

36.96

8.66

-2.92

.003**

Strategy Use

* Significant at /? < .05 (1-tailed)
** Significant at p < .01 (1-tailed)

disorders, (d) more positive beliefs about facilitating medication adherence being an
appropriate professional activity, and (e) higher self-reported use of specific strategies
to enhance adherence, than those who had not received prior training.

Relationship Between Beliefs and Self-Reported Strategy Use
Pearson's correlation was used to examine the relationship between beliefs
about medication (Overuse+Harm), beliefs about Adequacy, beliefs about the
Effectiveness of antidepressant medication, beliefs about facilitating medication
adherence being an appropriate professional activity {Role), and the extent of selfreported use of specific strategies to enhance adherence {Strategy Use). All variables
used in the analysis met the assumptions of normality. Pearson's correlations are
reported in Table 8. See Table 2 for the means and standard deviations for the
variables.
Results showed that the total score of the Strategy Use scale was negatively
correlated with Overuse+Harm scale. This indicates that the more participants
believed medications to be overused and harmful, the less they reported using
strategies to facilitate adherence. Adequacy was found to correlate positively with
Strategy Use, such that more positive beliefs about adequacy were associated with
higher reported use of strategies to facilitate adherence. Effectiveness was found to
correlate positively with Strategy Use, such that more positive beliefs about the
effectiveness of antidepressant medication were associated with higher reported use of
strategies to facilitate adherence. Role was found to correlate positively with Strategy
Use, such that more positive beliefs about facilitating medication adherence being an
appropriate professional activity were associated with higher reported use of strategies
to facilitate adherence.
Role correlated negatively with the Overuse+Harm scale indicating that more
positive beliefs about facilitating medication adherence being an appropriate
professional activity were associated with more positive beliefs about the overuse and

Table 8
Pearson Correlations (r) between Overuse+Harm, Adequacy, Effectiveness, Role,
and Self-Reported use of Strategies (Strategy Use) to Facilitate Adherence (N =72)

Scales

Overuse+Harm

Strategy Use

Role

Effectiveness

-.37**

-.47**

-.31*

Adequacy

.61**

.48**

.42**

Effectiveness

.48**

.52**

—

Role

.65**

—

Adequacy

-.18

—

* Significant at p < .01 (1-tailed)
** Significant at/? < .001 (1-tailed)

harmfulness of antidepressant medications. Role correlated positively with Adequacy
indicating that more positive beliefs about facilitating medication adherence being an
appropriate professional activity were associated with more positive beliefs about
adequacy. Role also correlated positively with Effectiveness indicating that more
positive beliefs about facilitating medication adherence being an appropriate
professional activity were associated with more positive beliefs about the
effectiveness of antidepressant medication.
Effectiveness correlated negatively with the Overuse+Harm scale indicating
that more positive beliefs about the effectiveness of antidepressant medication were

associated with more positive beliefs about the overuse and harm of antidepressant
medications. Effectiveness correlated positively with Adequacy indicating more
positive beliefs about the effectiveness of antidepressant medication were associated
with more positive beliefs about adequacy. No significant correlation was found
between Adequacy and the Overuse+Harm scale.

Factors Predicting Self-Reported Strategy Use

The final analysis was a standard multiple regression to determine which
factors (e.g., Overuse+Harm, Adequacy, Effectiveness, Role, and prior training)
predict Strategy Use when all variance is accounted for. The assumptions of normality
for the variables used in the multiple regression were met. Tolerance levels were not
found to be excessively low. No bivariate correlations were found to be over .70. The
results for the multiple regression are presented in Table 9.
Results revealed that the regression model was significant, accounting for 52%
of the variance in strategy use (F(5) = 16.39, p = .000; R^ = .55 and adjusted R^ = .52).
When all variance was accounted for, Role and Adequacy remained consistent
predictors of self-reported Strategy Use, This suggests that clinicians' greater
perceived adequacy and more positive beliefs that facilitating medication adherence is
an appropriate professional activity, predicted higher self-reported use of specific
adherence strategies.

Table 9
Summary of Multiple Regression for Scales Predicting Strategy Use (N =72)

Scales

B

SEB

P

p

Overuse+Harm

-.35

.35

-.10

.162

Adequacy

.75

.20

.37

.000*

Effectiveness

.51

.51

.10

.159

Role

1.70

.52

.37

.001*

Prior Training

.29

1.58

.02

.427

Note. Adjusted R^ = .52
** Significant atp < .01 (1-tailed)

Discussion

This study identified the views of primary care allied health clinicians about
their role in facilitating adherence among patients with depressive disorders, and
predictors of their self-reported use of adherence strategies.
Allied health clinicians in the study report a large proportion of their patients
with depressive disorders are prescribed antidepressant medication (64%) and almost
27% (ranging from 0% to 80% non-adherence) of these patients are non-adherent to
their prescribed antidepressant medication. This high rate of non-adherence is

comparable to the high rates of non-adherence among primary care patients reported
in previous research (see Aikens et al., 2005; Lin et al, 1995; Simon et al., 1993).
While most clinicians do not believe that patients with medication adherence issues
take up more time in session than patients who do not have these issues, the high rates
of non-adherence among patients suggests that there is a need for clinicians to spend
time facilitating medication adherence among their patients.
Given this need, it is encouraging that most clinicians believe facilitating
medication adherence is an appropriate professional role in which to engage and they
believe that they can adequately facilitate medication adherence. However, 30% do
not agree with or are unsure about whether facilitating medication adherence is an
appropriate professional role in which to engage. Approximately 50% of clinicians do
not agree that they can appropriately advise patients about their medication use.
Almost 50% indicate that they do not know enough about the risk factors for
developing medication adherence problems and over 30% are not satisfied with the
way they work with people with medication adherence issues. Furthermore, it is
concerning that over 60% of clinicians have not received any prior training on how to
facilitate medication adherence. This lack of training has been identified in previous
research, highlighting that many health clinicians do not appear to have received
adequate training in medication adherence strategies (Coombs et al., 2003; Byrne et
al., 2004, 2005).
A lack of previous training, disagreement about the appropriateness of
facilitating adherence, and clinicians' beliefs about their inadequacy to facilitate
adherence suggests that primary care allied health clinicians should be provided with
more opportunities to develop their ability to facilitate adherence. This is highlighted
by the finding that clinicians who had previously received adherence training reported

more positive beliefs about medication, adequacy, effectiveness of antidepressants,
and facilitating adherence being an appropriate professional activity in which to
engage. This has important implications for clinical practice as greater perceived
adequacy and acceptance that facilitating adherence is an appropriate professional
activity predict higher self-reported use of specific adherence strategies.
There is a need for a structured approach to training as the quality of prior
training appears difficult to evaluate. This is due to the diversity and inconsistency of
training methods (workshops, reading, and experience gained "on the job") and hours
(between 2 hours to 720 hours) that clinicians who have had training report receiving.
Almost 75% of allied health clinicians indicated that they agree with the
statement ''Antidepressant medication is an effective treatment for depressive
disorders". Conversely, some scepticism was observed in 75% of clinicians
disagreeing with the statement ''Depressed patients who take antidepressant
medication will get better''. Most clinicians believe that medications are overused but
do not believe that medications are harmful. In this study, 55% of clinicians believe
that medications are overused compared with reports that only 51% of patients believe
that medications are overused (Brown et al., 2005). Similarly, 63% of clinicians in
this study believe that doctors place too much trust in medications compared with
only 27% of patients (Brown et al.). These findings suggest that allied health
clinicians may be more sceptical than patients about the use of medication.
Patients who are sceptical about the use of medication demonstrate the lowest
rates of adherence to antidepressants (Aikens et al. 2005) which raises the question
about the potential role of clinician scepticism on the facilitation of adherence. The
belief that medications are overused has been found among 51% of pharmacists and
has been suggested as a barrier to effective communication between pharmacists and

patients (Ramstrom et al., 2006). Furthermore, clinician scepticism about the use of
medication has been suggested as an influence on the type of treatment patients
receive, including whether they receive support from their clinician to use their
medication more effectively (Byrne et al., 2005; Ramstrom et al., 2006; Stem et al.,
1999). The importance of ensuring that clinician's develop facilitative beliefs about
working with adherence issues is highlighted by the many useful strategies in which
clinicians can engage to facilitate adherence.
Clinicians indicate that they regularly discuss adherence issues with patients,
enquire about side effects, assess the possible causes of non-adherence, and encourage
patients to speak to their physician about medication adherence as strategies to
facilitate adherence. Interestingly, strategies that have been shown to effectively
influence patient medication adherence were reported to be regularly used by only
50% of the clinicians. Such strategies include motivational interviewing (Kemp et al.,
1996; Ludman et al., 2000; Rusch & Corrigan, 2002; Zygmunt et al., 2002), providing
information about antidepressant medication (as part of Cognitive Therapy, see
Aikens et al., 2005; Home & Weinman, 1999), problem solving (Miklowitz et al.,
2003; Zygmunt et al., 2002), and asking patients to monitor their adherence (as part of
developing a therapeutic alliance, see Weiss et al., 2002; as part of individualised
assessment, see Truax, 2001). This indicates that 50% of clinicians report that they do
not regularly use these important strategies to facilitate adherence.
This study showed that clinicians who had previously received training in
medication adherence strategies were more likely to report that they believe
medications are not harmful or overused, have a higher sense of adequacy in
facilitating adherence, believe antidepressant medication is an effective treatment for
depressive disorders, believe that facilitating adherence is an appropriate professional

activity in which they can engage, and use more strategies to facilitate adherence.
This further supports the need for training of primary care allied health clinicians
given that (a) the majority of clinicians in this study (64%) and in previous research
report that they have not received previous training (Coombs et al., 2003; Byrne et al.,
2004, 2005), and (b) clinicians' beliefs can be enhanced by such training (Byrne et al.,
2004).
Correlation analyses show that self-reported engagement in strategies to
facilitate adherence is related to clinicians' beliefs about medication and working with
adherence issues. Clinicians were most likely to report engaging in strategies to
facilitate adherence if they believed that medications were not harmful or overused,
held positive beliefs about their adequacy to facilitate adherence, believed that
antidepressant medication is an effective treatment for depressive disorders, and
believed that facilitating adherence is an appropriate professional activity in which
they can engage. Multiple regression analysis revealed that when all variance is
accounted for, more positive beliefs about adequacy and facilitating adherence being
an appropriate professional activity predict higher self-reported use of adherence
strategies. As the results from this study and previous research show, clinicians'
beliefs about the use of medication influence the treatment that patients receive, such
that more positive beliefs are associated with more regular engagement in strategies to
facilitate adherence (Byrne et al., 2005; Farris & Schopflocher, 1999; Ramstrom et
al., 2006). Furthermore, the results from this study are supported by previous findings
that report clinicians' beliefs about adequacy to facilitate adherence are a direct
predictor of behaviour, such that more positive beliefs about adequacy are associated
with more regular engagement in strategies to facilitate adherence (Bandura, 1997;
Farris & Schopflocher, 1999). A novel finding of this study is that more positive

beliefs about whether facilitating adherence is an appropriate professional activity in
which to engage is also a predictor of higher self-reported use of adherence strategies.
This finding has implications for professional degree programs where clarification of
professional roles around supporting medication use may need to be improved.
The generalisability of these findings to all allied health clinicians is limited
given that the sample was predominately psychologists. However, these findings
provide important information about the current practices of psychologists delivering
services in primary care. Since being introduced, there has been an extremely high use
of government funded psychological services by primary care patients. There have
been a number of media releases (e.g. by the Australian Psychological Society) about
the higher than expected uptake, suggesting that over time, more patients are going to
be referred by primary care physicians and seen by psychologists. The proportion of
other allied health professional groups working in primary care is not known and
should be addressed in future research to ensure generalisability of these findings to
all allied health clinicians, not just psychologists. Finally, as this study relied on selfreport of clinicians' beliefs and behaviours it is difficult to determine whether these
findings are a true reflection of clinicians' actual beliefs and work practices.
In summary, this study identified that allied health clinicians working in
primary care believe that facilitating patient adherence to antidepressant medication is
an appropriate professional role in which they can engage. The extent to which they
engage in such strategies is influenced by ih&ii beliefs about medications, beliefs
about adequacy to facilitate adherence and prior training in medication adherence
strategies. The findings suggest that primary care allied health clinicians should
receive structured training in facilitating medication adherence among patients with

depressive disorders to enhance their skills, knowledge, and beliefs necessary to
facilitate adherence.

STUDY 2:
TRAINING CLINICIANS TO FACILITATE ADHERENCE TO
ANTIDEPRESSANT MEDICATION AMONG INDIVIDUALS WITH
DEPRESSIVE DISORDERS

This study examined the delivery of an adapted Medication Alliance program
(Byrne et al., 2004) for allied health clinicians working with individuals with
depressive disorders who are non-adherent to antidepressant medication. The impact
of training on clinician (1) knowledge of medication adherence issues and ways to
facilitate adherence, (2) skill to use a specific medication adherence strategy
(identifying causal variables for non-adherence), and (3) beliefs about working with
individuals who are non-adherent and beliefs about the use of medication, was
explored. Modifications to the original program (Byrne et al., 2004) included; (1) a
change in training content to ensure training specifically covered the issues related to
facilitating adherence among individuals with depressive disorders and, (2) a
reduction in adherence training time from 3 days to 2 days for Medication Alliance
training.
It was hypothesised that the modified Medication Alliance training program
would significantly enhance clinician knowledge, skill and beliefs to facilitate
adherence among individuals with depressive disorders. Examination of the effect of
training on clinicians' general beliefs about the use of medication was of an
exploratory nature and no predictions were made.

Method

Participants

Participants were recruited for the study via poster advertisement in their
places of work (primary care offices within Southern Health, Victoria's largest
metropolitan health service). The advertisement stated that the training was part of
voluntary workplace training. Interested clinicians were invited to register for training
(contact details were supplied on the advertisement poster). No inclusion criteria were
applied. Participants were nurses and allied health clinicians involved in the Better
Outcomes in Mental Health Care program, and allied health clinicians from a primary
mental health team. One participant in private practice was included in the training.
A total of 24 clinicians participated in the training, and 22 provided
demographic information. Eight were psychologists (36%), 6 social workers (27%), 6
nurses (27%), 1 occupational therapist (5%), and 1 research fellow (5%). Of the
participants who gave demographic information, 17 were female (77%). The mean
age of participants was 40.71 years (range 23 to 59 years). The average length of time
working in their current profession was 13.86 years (range 1 to 40 years) and the
average length of time employed in their profession specifically in a mental health
setting was 10.21 years (range 1 to 26 years). Three participants (14%) stated they had
not previously worked in a mental health setting.
Nineteen participants (86%) reported they had active caseloads and were all
working with patients with a depressive disorder. Participants reported 91.6% (range
of 30% - 100%) of their patients with depressive disorders were taking antidepressant
medications. Of these patients, 23.3% (range 0% - 75%) were variable in their

medication adherence. Only four participants (18%) reported they had previously
received training specifically related to medication adherence issues.
Materials and Procedure
Training consisted of a 3-day workshop facilitated by the researcher (DF) and
one of the trainers from the original Medication Alliance workshops (Byrne et al.,
2004). The first day of training provided participants with a review of information
regarding the nature of depressive disorders and the current assessment tools and
treatment options available. This was followed by two days of Medication Alliance
training. An outline of the Medication Alliance workshop program (days 2 and 3) is
shown in Table 10. The reduction of Medication Alliance training to two days is
significant in terms of feasibility of delivery, given that the original program was
delivered over three days (Byrne et al., 2004). The additional day of training (day 1)
was incorporated into the program given the diverse range of health professionals
involved in the training to ensure adequacy of knowledge of depressive disorders
prior to Medication Alliance training. This additional information was adapted from
the Mental Health Aptitudes into Practice (MAP) training programs
(http://www.bevondblue.org.au) (Monash University & Beyondblue: The National
Depression Initiative, 2004a,b). Material covered during day 1 of training was not
assessed in the pre- or post- training evaluation.
The workshop incorporated didactic teaching, demonstration of skills and
opportunity for participants to practice skills in small groups. Training was facilitated
according to a series of power point slides, supported by an adapted version of the
original Medication Alliance training manual (Byrne et al., 2003). An overview of the

Table 10
Overview of Medication Alliance Training Program (Days 2 and 3 of Training) for
Individuals with Depressive Disorders

Medication Alliance Technology: An Introduction
Normalising non-adherence
What is non-adherence?
What influences adherence?
The clinician role in medication adherence
Engagement
Agenda Setting, Information Sharing, Normalising Rationales, Empathy
Assessment
Illness Timeline, Functional Analysis <& Case Formulation
Therapy
Motivational Interviewing strategies, Cognitive Behavioural strategies (for
thoughts, feelings and concerns about medications). Problem Solving and
Homework
Evaluation
Homework
Integration of Core Concepts

content of the original Medication Alliance training program was elaborated earlier
(pp. 36 - 49). The adapted version for this study (Byrne & Feros, 2004a, see
appended CD-ROM file Medication Alliance with people who have depressive

disorders: Training manual) included content changes to ensure training material
reflected issues relevant for working with individuals with depressive disorders as the
original program (Byrne et al., 2003; Byrne et al., 2004) had a focus on working with
individuals with psychosis. Training covered a range of techniques previously found
to be effective in the enhancement of medication adherence including motivational
interviewing, cognitive behavioural strategies, and problem solving skills (Gray et al.,
2003; Kemp et al., 1996). Also included was a focus on variables found to
consistently predict adherence including the patient-clinician relationship (Delgado,
2000; Demyttenaere, 1997), and addressing patient beliefs that are barriers to
medication adherence (Aikens et al., 2005). Participants were provided with
workshop booklets that included a copy of all power point slides and handouts used
during the workshop to demonstrate skills (Byrne & Feros, 2004b, see appended CDROM file Medication Alliance with people who have depressive disorders: Trainee
resource book 1, 2, and 3).
Measures
All measures were taken at the beginning of the first day of training (pretraining) and were repeated at the end of the last day of training (post-training). See
Appendix B for a copy of the pre-training measures.
Knowledge
The Medication Alliance Clinical Knowledge Questionnaire is a 15-item
multiple-choice questionnaire. Questions were adapted from a previous knowledge

questionnaire used in Medication Alliance training (Byrne et al., 2004). Adaptations
for this study were developed from depression-specific aspects of the training material
and were designed to test participant knowledge of medication adherence issues and
ways to facilitate adherence. Four multiple-choice options were given for each
question and participants were asked to circle the most accurate response. Scores
could range from 0 to 15.
Skill
The Individualised Assessment Exercise was used for the Skill measure. It
consisted of a case vignette of a patient with a depressive disorder who was variable
in their adherence to antidepressant medication. Participants were asked to identify as
many possible variables influencing the patient's adherence, as well as the most likely
variables influencing adherence, based on the information provided in the vignette.
Most likely variables were included in the list of possible variables but were viewed as
variables that implied 'causality' of non-adherence in the sense that they occurred
immediately prior to a reduction in adherence. A total of 9 possible variables and 5
most likely variables were imbedded within the vignette.
Beliefs
Medication Alliance Beliefs Questionnaire.
The MABQ (see Study 1) is a 22-item questionnaire which explores clinician
beliefs about working with individuals who are non-adherent to medication (Byrne et

al., 2004). Items are rated on a 5-point Likert scale where 1 = "Strongly Disagree"
through to 5 = ''Strongly Agree'\ Higher responses indicate more positive beliefs with
the exception of the Pessimism scale where higher responses indicate higher levels of
pessimism. For data analysis and for consistency in reporting of results, the scores on
the pessimism subscale were reverse scored.
The original MABQ was comprised of 5 subscales including Adequacy,
Legitimacy, Motivation, Work Satisfaction, and Self Esteem (Gorman & Cartwright,
1991). Byrne et al. (2006) have since used this questionnaire with a sample of 292
mental health clinicians. Factor analysis yielded 5 subscales that were highly similar
to the original version of the measure and were used in the present study: Adequacy,
Empathy, Pessimism, Work Satisfaction, and Self Esteem. Cronbach alpha coefficients
in the Byrne et al. study (see below for coefficients) show sufficient internal
consistency for the subscales.
The Adequacy (a = .83), subscale measures how effectively the clinician
believes they are able to help individuals with medication adherence issues based on
their knowledge and skill level (e.g. '7 feel that I can appropriately advise people
about the use of their medications'"). The Adequacy subscale used in this study is
identical to \he Adequacy subscale used in Study 1.
The Empathy subscale (a = .60) measures the clinician's level of empathy for
individuals with medication adherence issues (e.g. ''I find it hard to imagine what it
might be like to have medication adherence issues").
The Pessimism subscale (a = .65) measures the level of pessimism the
clinician holds towards working with individuals with medication adherence issues
(e.g. "/feel that there is little that I can do to help people who have medication
adherence issues").

The Work Satisfaction subscale (a = .72) measures the level of satisfaction the
clinician believes they obtain from working with individuals with medication
adherence issues (e.g.

general, it is rewarding to work with people who have

medication adherence issues'').
The Self Esteem subscale (a = ,63) measures how much the clinician believes
they have the personal ability to help individuals with medication adherence issues
(e.g. "Ai times I feel I am no good at working with people who have medication
adherence issues").

Beliefs about Medicines Questionnaire.

The General scale of the BMQ (see Study 1) is an 8-item questionnaire
originally developed by Home et al. (1999) to identify clinicians' beliefs about the
overuse and harmfulness of medication. The scale items are rated on a 5-point Likert
scale from 1 = ''Strongly Disagree'' to 5 = ''Strongly Agree". The items provide two
subscales, Overuse (e.g., "Doctors use too many medications") and Harm ("All
medications are poisons").

Results

Statistical analyses were performed using the SPSS for Windows (v. 15.0)
(SPSS Inc., 2006). Of 24 participants 20 completed all pre- and post-training
measures, 2 completed pre-training measures, and 2 completed post-training measures
only. Missing data from the 4 participants who did not complete all pre- and posttraining measures was replaced with item means of the total remaining sample of

participants (Tabachnick Se Fidell, 2001). Matched samples i-tests were performed to
assess pre- and post-training outcomes. The assumptions of normality for i-tests were
met for all variables. In an effort to control Type I error for multiple comparisons, a
Bonferroni adjustment (a = .005) was applied. The significant effects on knowledge
and beliefs about adequacy and work satisfaction (reported below) are sustained, even
when the Bonferroni was applied.

Knowledge

Statistical analyses for the Knowledge measure are reported in Table 10. The
post-training mean score for Knowledge was significantly higher than the pre-training
score. A large effect size for Knowledge was obtained

= 1.51; Howell, 1997).

Skill

Interrater reliability was conducted for the Skill measure with raters blind to
pre- and post-training conditions. Raters were two clinical psychologists who were
trained to rate the skill measure in a 60 minute workshop. Training included reading
through the skill measure and answers, and practicing scoring of the measure using
answers generated for training purposes. Scores were based on the content of
participants' answers, not the total number of answers participants provided (e.g.,
there were 9 specific possible variables and 5 specific most likely variables that, if
written as an answer, could receive a score). Scoring criteria for content was provided
to the raters. Pearson's correlation was used to determine interrater reliability for each
of the variables. The assumptions of normality for conducting the correlation were
met for all variables. The correlations for the total number of variables identified as

correct for each respondent were r = .94 (possible variables, pre-training), r = .93
(possible variables, post-training), r = .86 (most likely variables, pre-training), and r =
.70 (most likely variables, post-training).
Statistical data for the Skill measure can be found in Table 11. A small to
moderate effect size (d = .37) was obtained for the increase in the number of possible
variables identified from pre- to post-training. However, the increases in both the
number of possible variables and most likely variables identified from pre- to posttraining did not reach significance.
Beliefs
Table 11 shows statistical data for the subscales of the MABQ and the BMQ.
For the MABQ, a significant increase in beliefs on the Adequacy and Work
Satisfaction subscales was obtained. A large effect size was obtained for the increase
in Adequacy beliefs (d = 1.50). No significant differences were found on the
Pessimism, Self Esteem, and Empathy subscales, though small to moderate effect sizes
(d= 30, d= .42, J = .56, respectively) were obtained. As the items on the Pessimism
scale were reverse scored, a higher pessimism score indicates less pessimism.
Differences over training in the Self Esteem and Empathy subscales would have
reached significance if the Bonferroni adjustment was not applied. For the BMQ, no
significant difference in beliefs was obtained on either the Overuse or Harm
subscales.

Table 11
Means (M), Standard Deviations (SD), t-Test Statistics, and Effect Sizes (d)for
Knowledge, Skill, and Beliefs (MABQ and BMQ) (N = 24)

Scale/subscale

Score
range

Mpre (SD)

Mpost (SD)

t

d

P

0 - 15

6.18 (2.04)

9.27(1.75)

-5.96

1.51

.000*

Possible

0 - -9

4.73 (2.09)

5.50 (2.10)

1.47

.37

.155

Most likely

0 --5

.91 (1.02)

.95 (0.69)

-.21

.04

.833

Adequacy

6 - 30

18.45 (3.93)

24.36 (2.68)

-7.54

1.50

.000*

Work Satisfaction

3 - 15

10.14(2.35)

11.59 (1.49)

-3.35

.62

.003*

Self Esteem

4 - 20

15.91 (2.95)

17.14 (2.09)

-2.68

.42

.014

Pessimism

3 - 15

13.05 (2.07)

13.68 (1.94)

-1.49

.30

.150

Empathy

3 - 15

11.36(1.52)

12.27 (2.05)

-2.48

.56

.021

Overuse

4 - 20

11.55 (3.07)

12.14 (2.58)

-1.50

.19

.147

Harm

4 - 20

8.14 (2.31)

7.52 (2.33)

1.66

.27

.112

Knowledge
Skill

MABQ

BMQ

*p< .005, Bonferroni adjusted,!-tailed

Discussion

Study 2 examined the impact of a medication adherence training program on
primary care allied health clinicians' knowledge, skill, and beliefs to facilitate

medication adherence among individuals with depressive disorders. The importance
of delivering such an intervention is highlighted by the lack of such training delivered
specifically to allied health clinicians working with individuals with depressive
disorders. Furthermore, this research is unique in that the training program was
significantly reduced from 3 (see Byrne et al., 2004) to 2 days; a modification that
makes the training more appealing to an Australian primary care context.
After attending a 2-day modified version of Medication Alliance (Byrne et al.,
2004), clinicians showed significant improvements in their knowledge and beliefs.
On average, clinicians correctly answer three more knowledge questions out of a total
of 15 post-training. Beliefs about adequacy and work satisfaction improved over the
course of training. However, the 2-day modified version of Medication Alliance
demonstrated no significant improvements on the skills measure. Prior to training,
clinicians could identify an average of five out of nine possible variables that may
influence a patient's use of antidepressant medication. At post-training, clinicians
only identified an average of one extra possible variable, taking the total possible
variables identified post-training to an average of six out of nine. The absolute level
of achievement when identifying the most likely variables that influence adherence is
one out of five pre-training. This is low and does not increase post-training.
From these results, the 2-day modified version of Medication Alliance is
useful for improving allied health clinician knowledge and beliefs. The results do not
significantly demonstrate it's utility for improving skill. The non-significant result for
skill could be attributed to a reduction in training time, given that three days of
training (see Byrne et al., 2004) has previously demonstrated significant skill
improvements. Byrne et al. found a significant increase in the number of possible
variables identified from four out of nine pre-training, to five out of nine post-

training. Byrne et al. also found a significant increase in the number of most likely
variables identified from one out of five pre-training, to two out of five post-training.
However, the results from the Byrne et al. study show only a small increase in the
number of variables identified, which is not unlike the modest changes found in the
current study. Medication Alliance training over 3 days (see Byrne et al.) may allow
for more skills practice than the modified 2-day version used in this study. However,
the significant difference in skill obtained utilising the original 3 days of training
compared with the 2-day version in the current study is only a small effect to justify
adding an extra day of training. Maintaining the 2-day program would help to retain
the appeal that such a brief program has in an Australian primary care context. The
skill based exercises during training focuses on individualised assessment and
functional analysis. Therefore, devoting more of the training time to practicing these
specific skills over the two days may help to improve the impact of training on the
skill measure, whilst maintaining brief 2-day training. Perhaps clinicians could be
asked to practice the skills covered in between days of training as homework to allow
for more time with the Medication Alliance training material as opposed to adding
another day of training.
Another consideration for the lack of increase in clinician skill is the moderate
interrater reliability reported for the number of most likely variables identified both
pre-training (r = .86) and post-training (r = .70). This suggests that there is only
moderate agreement among raters on the content of the most likely variables
identified. To address this issue, the scoring criteria of the skill measure should be
revised to include more clear descriptions of correct answers and perhaps multiple
examples of how such answers may be written by participants. In addition, the raters

should be trained for a longer period of time to allow for more examples of scoring to
be carried out and compared.
This research demonstrates that allied health clinicians can be trained in the
areas of knowledge and beliefs necessary to facilitate medication adherence in a short
amount of time (e.g. 2 days). This is an important finding given that Study 1 showed
that more positive beliefs are related to higher self-reported use of adherence
strategies. In addition, previous research has not specifically demonstrated changes in
allied health clinicians' knowledge and beliefs necessary to facilitate adherence
(Byrne et al, 2004; Gray et al., 2003). Rather, previous research has focused on
enhancing the skills, knowledge, and beliefs of mental health nurses who already are
assumed to have a role in facilitating adherence (Coombs et al., 2003). The
importance of focusing on allied health clinicians is highlighted by the findings in
Study 1 that indicate that while most clinicians believe that facilitating adherence is
an appropriate professional activity in which to engage, up to 30% do not agree or
were uncertain. In addition, beliefs about facilitating adherence being an appropriate
professional activity predict self-reported use of specific adherence strategies.
Furthermore, training allied health clinicians is important in an Australian primary
care context as a range of allied health clinicians are responsible for providing
services to primary care patients with depressive disorders under a raft of government
initiatives (e.g., Better Outcomes in Mental Health Care and Enhanced Primary
Care).
Over the course of training, clinicians showed a significant increase in beliefs
about their adequacy to facilitate adherence {Adequacy) and the satisfaction they
obtain from working to facilitate adherence {Work Satisfaction). There were also
indications that empathy they hold for individuals who are non-adherent {Empathy),

and their ability to help individuals who are non-adherent {Self Esteem) improved.
Medication Alliance has previously been found to influence only beliefs about
adequacy and work satisfaction (Byrne et al., 2004). This suggests that the
modifications made to the program for this study do not compromise the extent to
which beliefs are addressed in training.
A large effect size was found for the increase in adequacy beliefs after
training, suggesting that Medication Alliance training can significantly enhance these
beliefs over a 2-day training period. This is a significant finding given that the beliefs
that clinicians hold about their ability to facilitate adherence have been suggested to
significantly influence the degree to which they work to facilitate adherence among
their patients (Byrne et al., 2005; Farris & Schopflocher, 1999; Ramstrom et al.,
2006). The importance of the relationship between adequacy beliefs and engagement
in strategies to facilitate adherence was also demonstrated in Study 1. Specifically
clinicians who had more positive beliefs about their adequacy to facilitate adherence
were more likely to report using strategies to facilitate adherence. This is further
strengthened by the finding, in Study 1, that more positive beliefs about adequacy
predict higher self-reported use of specific strategies to facilitate adherence.
Importantly then. Study 2 has shown that Medication Alliance training is able to
significantly improve adequacy beliefs. A question to be addressed by future research
is, does this improvement in adequacy lead to improvements in actual practice (e.g.,
observed use of specific adherence strategies)?
Clinicians' pessimism about working with individuals who are non-adherent
to antidepressant medication did not significantly change over the course of training.
This result was likely obtained due to a ceiling effect observed for the measure of

pessimism. On pre-training measures, clinicians reported very low pessimism (i.e. M
= 13.05 out of a total of 15).
Ratings of beliefs about the use of medication suggest that clinicians, on
average, do not hold strongly negative or positive beliefs about medication being
harmful or overused. Rather, the data suggests that there is a degree of variation in
clinicians' general beliefs about medications being harmful or overused. Training
does not appear to have a significant impact on clinicians' general beliefs about
medication. This is likely to have not changed as a result of training as the issues
surrounding the overuse and harm of antidepressant medications were not specifically
targeted during training. Furthermore, clinicians' beliefs about specific medication, in
this instance antidepressants, were not assessed. The BMQ assesses clinicians' beliefs
about medications in general. If the assessment of beliefs was specific to beliefs about
antidepressants, the data may have more explanatory power. This may be a topic for
future research. Obtaining information about general beliefs is important in this study
given the influence that such beliefs can have on clinicians' engagement in
medication adherence strategies (see the results from Study 1; Byrne et al., 2005;
Farris & Schopflocher, 1999; Ramstrom et al., 2006). The fact that this study shows
clinicians' beliefs about medication are not strongly negative, even prior to training, is
a positive finding given the influence these beliefs can have on the type of treatment
provided to patients by clinicians (Byrne et al., 2005; Farris & Schopflocher, 1999;
Ramstrom et al., 2006).
The clinicians in this study report an average rate of 23% (range 0% - 75%) of
their patients on antidepressant medication were non-adherent. This rate of nonadherence is slightly lower than the average rates of non-adherence reported in
previous research for similar patient groups; 27% (Study 1), 35% (Cramer &

Rosenheck, 1998), 25% (Aikens et al., 2005), between 28% and 35% (Lin et al.,
1995; Simon et al., 1993), and 60% (Katon et al, 1992). The difference in rates of
non-adherence may be explained by different measurements of adherence (e.g. self
report compared with pill counts) and the length of time patients have already been
taking medication. For example, Aikens et al. report 25% non-adherence over a 2week period and Katon et al. reports higher rates of 60% non-adherence over a 6month period.
Only 18% of clinicians reported they had received previous training in
medication adherence strategies which further reinforces previous findings that health
clinicians do not appear to receive adequate training in medication adherence
strategies (Coombs et al., 2003; Byrne et al., 2004, 2005). Furthermore, this lack of
previous training highlights the importance of providing training, given evidence that
training can improve clinicians' skills, knowledge, and beliefs necessary to facilitate
medication adherence (Byrne et al., 2004; Gray et al., 2003). In Study 1, 36% of
clinicians reported that they had received previous training. The significantly lower
rate of clinicians from this study who report receiving previous training may be due to
different training opportunities available across Australia as clinicians from Study 1
were predominantly from New South Wales while clinicians from Study 1 were from
Victoria.

Limitations

This study has a number of limitations. Firstly, it examines the impact of
training on a relatively small sample without a control group for comparison.
Therefore, the results should be interpreted with some degree of caution. The

inclusion of nurses in the participant sample does not make this sample a pure allied
health clinician sample. Therefore degree of representation that this sample provides
for allied health clinicians is limited, reducing the generalisability of the results.
However, given the diversity of the participant sample, the results suggest that
Medication Alliance techniques can be delivered to a wide range of mental health
clinicians, an important step toward improving care for individuals with medication
adherence issues (Sawyer & Aroni, 2003). A lack of follow-up of participants after
training does not allow determination of whether the changes demonstrated
immediately post-training are maintained over time.
There is a need for a more thorough assessment of clinician skill. For example,
the study did not include a video or audiotape of actual samples of clinicians' skills in
either role plays or with actual patients. Finally, the exclusion of the Role scale (see
Study 1) is a limitation. Study 1 found that clinicians who had previously received
training had significantly more positive Role beliefs. In addition, clinicians' Role
beliefs predicted self-reported use of adherence strategies. It is therefore
recommended that the Role subscale be included in future studies of Medication
Alliance training. It may be possible that clinicians seeking Medication Alliance
training may already view facilitating adherence as an appropriate professional role in
which to engage. In that case, significant changes may not be observed on the Role
subscale over the course of training. Nevertheless, it is worth investigating this in
future studies.

CONCLUSIONS

Depression is highly prevalent among primary care patients. However, up to
44% of patients do not adhere to prescribed antidepressant medication (Lin et al.,
1995). Interventions to increase patient adherence often involve highly trained
clinicians such as physicians, psychiatrists, and clinical psychologists (Katon et al.,
1999, 2001, 2002; Ludman et al., 2000; Mündt et al., 2001; Vergouwen et al, 2005).
In Australia adherence interventions may be delivered by a range of clinicians such as
allied health clinicians given the structure and funding of government health
initiatives (e.g., Better Outcomes for Mental Health Care Program and Enhanced
Primary Care). This research identified allied health clinicians' views about
facilitating adherence in primary care, the extent to which they engage in strategies to
facilitate adherence, and the impact of a Medication Alliance training program on
knowledge, skills, and beliefs, necessary to facilitate adherence.
Study 1 identified beliefs held by primary care allied health clinicians about
working with patients with depressive disorders who are non-adherent to
antidepressant medication. Overall, clinicians believe that antidepressant medication
is an effective treatment for depressive disorders and that facilitating adherence is an
appropriate role in which they can engage.
However, many clinicians had not received adequate training in medication
adherence strategies. This supports previous findings that clinicians lack the skills,
knowledge, and beliefs necessary to facilitate adherence (Byrne et al., 2005; Coombs
et al., 2003; Gray, Wykes, Parr, Hails, & Goumay, 2001). Clinicians' beliefs about
medications, their adequacy to facilitate adherence, and their belief that facilitating
adherence is an appropriate professional activity, are found to have an impact on the

extent to which they engage in strategies to facilitate adherence. Specifically,
clinicians who hold more positive beliefs about medication and their adequacy to
facilitate adherence, are more likely to engage in self-reported strategies to facilitate
adherence than clinicians with negative beliefs. Study 1 shows that clinicians who
have received prior training in medication adherence strategies are more likely to hold
positive beliefs about medication and their adequacy to facilitate adherence, and
report greater use of strategies to facilitate adherence than clinicians who have not
received training. This highlights that there is a clear need for training in medication
adherence strategies among primary allied health clinicians working with individuals
with depressive disorders who are non-adherent to antidepressant medication.
In order to address the need for training among primary care allied health
clinicians, a modified version of Medication Alliance (Byrne et al., 2004) training was
delivered to 24 primary care allied health clinicians (Study 2). Over the course of
training, clinicians demonstrated significant increases in knowledge about medication
adherence issues and ways to facilitate adherence, and beliefs about working with
individuals who are non-adherent to antidepressant medication. No significant
increase in skill was demonstrated after training. This may be due to only moderate
interrater reliability of the measure or the reduction in training time from 3 days
(Byrne et al., 2004) to 2 days, compromising the amount of time for skill practice.
Overall, the results suggest the Medication Alliance training can be modified
for delivery to allied health clinicians working in primary care setting with individual
with depressive disorders, and still improve knowledge and adequacy beliefs. The
delivery of such training to a range of health clinicians is an important step toward
improving care for primary care patients (Sawyer & Aroni, 2003). The next step in
this research is to examine the impact that training has on clinical practice and

whether clinicians who receive training do engage in more use of specific medication
adherence strategies than clinicians who do not receive training. The development and
ongoing evaluation of training programs such as Medication Alliance are important
steps in improving primary health care for patients with depressive disorders.
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APPENDIX A

Allied Health Beliefs Questionnaire
Section AI
Please place a cross M in the box next to the answer that is relevant for you.
1. Gender:

Male D

3. Profession:

Female

Psychologist

D

2.

Age:

Social worker L I Occupational Therapist

Other
4. Highest degree:

PhD
Bachelor

Masters

DPsyc

Honours

Other

•

5. Years worked in your profession (question 3) since accredited:
6. Number of hours worked per week in your profession (question 3):
0-10 •

10-20

30-40

20-30

40 +

7. In what State do you practice:
8. What is the name of your local Division of General Practice:
If unsure, a map of Australia wide Divisions can be found at www.gp.org.au

9. Do you work in a clinical capacity with patients with a mental illness (e.g.
providing case management, assessments, treatment, conducting therapy):
Yes'

No l—J No, go to 12

10. Is any of your clinical work with patients associated with:
Better Outcomes for Mental Health Care:

Yes

No

Enhanced Primary Care program (Medicare):

Yes

No

11 What is your predominant theoretical model when conducting therapy with
patients:
12. Which best describes the type of agency you work in:
Community Health Centre
Hospital •

Private practice

Community Mental Health Centre
Other

13 How many patients do you currently have on your caseload:.

Section R
This section includes questions about your general beliefs about medications.
There are no right or wrong answers, so please provide your honest opinion.
Please use the following response scale and place a cross M in the box that best
represents your belief.
Strongly Disagree
Disagree
1 Doctors use too many medications

1

2

Uncertain

Agree

3

4

Strongly
Agree
5

2 People who take medications should stop
their treatment for a while every now and
again
3 Most medications are addictive
4 Natural remedies are safer than medications
5 Medications do more harm than good
6 All medications are poisons
7 Doctors place too much trust on medications
8 If doctors had more time with patients they
would prescribe fewer medications

Section C
This section includes questions about your general beliefs about assisting
patients to make effective use of their psychotropic medications. There are no
right or wrong answers, so please provide your honest opinion. Place a cross ISI
in the box that best represents your belief.
Strongly
Disagree
1 I feel I know enough about the reasons why
people don't use medications to carry out my
role when working with people who have
medication adherence issues
2 I feel I know how to counsel people who have
medication adherence issues over the long
feel that I can appropriately advise people
3 Iabout
rhp of their medications
Yf^Qi^mTTh^
a working knowledge of
4
mrHinfio" iidherence issues
with the way I
5 work with people who have medication
_adhaenceissues

1

Disagree Uncertain

Agree

Strongly
Agree
5

I feel I know enough about the factors which
put people at risk of developing problems
with the use of their medications to carry out
my role when working with people who have
medication adherence issues

Strongly
Disagree
1

Disagree Uncertain
2

3

Agree
4

Strongly
Agree
5

Section D
This section asks questions specific to your work with individuals who have
depressive disorders and who have been prescribed antidepressant medication,
1. What percentage of the patients on your caseload have a depressive
disorder?
2. What percentage of your patients with a depressive disorder have been prescribed
antidepressant medication?
3. What percentage of you patients with a depressive disorder who have been
prescribed antidepressant medication do you think are non-adherent or variable in
their adherence to their medication?
4. How true is it that patients who are non-adherent or variable in their adherence to
antidepressant medication occupy more of your time than those who are adherent
to antidepressant medication? (Please circle a number).
8

1

Not At
All True

9
10
Completely
True

5. The following questions ask about your beliefs about patients with depressive
disorders who have been prescribed antidepressant medication. There are no
right or wrong answers so please provide your honest opinion. Place a cross 0 in
the box that best represents your belief.
Strongly
Disagree
I
li

Antidepressant medication is an effective
treatment for depressive disorders
" Antidepressant medication helps to
reduce the symptoms of depressive

who take
lii -^¡r;:;;;^dpatients
nntidfC!Hsant medication will get better
adhere to antidepressant
Iv ^jgi^in^atients
medication is an appropriate professional
-„f^ritv fnr me

1

Disagree Uncertain

Agree

Strongly
Agree
5

Strongly
Disagree
1

Disagree

Uncertain

Agree

Strongly
Agree
5

It is appropriate for clinicians without
medical training to assist patients with
medication adherence

6. The following questions ask about the extent to which you engage in the
following activities in your work with patients with depressive disorders who
have been prescribed antidepressant medication and are variable in their
adherence to anti-depressant medication. There are norightor wrong answers so
please provide your honest opinion. Place a cross ISI in the box that is most
relevant for you.

I
li
lii
Iv
V
Vi
Vii
viii
Ix
X
Xi

7

Not At
All

A Little

Sometimes

Often

1

2

3

4

I do not get involved with my patient's
medication adherence
I use specific interventions to enhance
medication adherence
I consult with a physician about my
patient's medication adherence
I discuss medication adherence issues
with my patients
I enquire about medication side effects
with my patients
I ask my patients to monitor their
medication adherence
I provide patients with information about
medication
I assess the possible causes of my
patient's medication non-adherence
I provide motivational strategies to help
my patients with adherence to medication
I encourage my patients to speak to their
physician about medication adherence
I use problem solving strategies to
overcome medication non-adherence
Have you received training on how to enhance medication adherence?
Y e s U Nol—

8

If yes, please estimate the number of hours involved in the training: ...

9

Please briefly describe what the training involved:

Thank you for completing this questionnaire.

Almost
Always
5

APPENDIX B
Medication Alliance Pre-Training Measures Booklet

Medication
Alliance

With People Who Have Depressive Disorders

Better Outcomes in Mental Health
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1. Name

2. Date

3. D.O.B.

4. Gender

5. Profession
6. Qualifications
7. Year of completion of highest
qualification
8. Current position title
9. Number of years worked in
profession
10. Have you ever worked in mental
health services?

•

yes •

no

•

yes •

no

•

yes •

no

11. If yes, for how long?
12. Have you ever attended training
related specifically to medication
adherence issues?
13. If yes, please outline what the
training involved, including an
estimate of number of training
hours and specific content areas
(e.g., as part of a university
course, as an in-service etc)
14. Have you ever attended training
related specifically to mmdfulness
or meditation?
15. If yes, please outline what the
training involved, including an
estimate of number of training
hours and specific content areas
16. How many patients do you have
on your caseload?
17. How many of your patients have a
major depressive disorder?

18. How many of those patients with a
major depressive disorder are
prescribed antidepressant
medication?
19. How many of those patients
prescribed antidepressant
medication are non-adherent or
variable in adherence to
medication?
20. Of those patients on your case load
who
• have depression
AND
• have been prescribed
antidepressant medication
AND
• are variable or non-adherent in
their medication use
estimate how often you consult
with them (tick box)

•
•
•
•
•
•
•

more than twice per week
twice per week
once per week
once per fortnight
once per month
every three months
less than quarterly

21. How true is it that patients who are
non-adherent occupy more of
your time than those who are
adherent to antidepressant
medication?
1
2
not at all true

9
10
completely true

Individualised Assessment Exercise
Please read the following vignette and answer the question: "What may be influencing
Angeláis use of medication?" In the first column, please list factors that may possibly be
influencing Angela; and, in the second column, list those factors that are likely to be
influencing her ('causal variables'). Recording your answer in dot points is fine. Please
use the answer sheet provided.
Angela is a 29-year-old single mother with one child. She studies part-time at the local
university and has managed to maintain acceptable grades. She has major depressive disorder
that has been well managed on antidepressant medication, although over the last month she
has become increasingly variable at taking her medication, intermittently missing doses, and
consequently is becoming unwell. You are wondering why this is so when she is so attached
to her child and last time she stopped medication her daughter was placed in care. You
therefore gathered the following information from her in order to undertake a functional
analysis.
Angela had been managing quite well financially on her supporting parent benefit and the
maintenance paid by the father of her child. However her former partner was sent to jail three
months ago and the maintenance money he was sending her dried up. As a consequence, she
started falling behind in some bills about 8 weeks ago and she has discussed with you how
this worries her. On top of this, her daughter started teething last week and is cranky most of
the time. Angela has said that she thinks that her daughter is more distressed than normal and
believes that her local GP did not take her concerns about her daughter's distress seriously
enough when she took her to see him 10 days ago. In fact, Angela has wondered for some
time if the GP even cares about her welfare at all.
Angela appears to have a positive personal life, meeting a new man 6 weeks ago for whom
she cares a lot. He is a little younger than her and she says they enjoy each other's company
considerably, though sometimes Angela finds him a little too energetic. With all the increased
activity with her boyfriend, she would forget her medication routine from time-to-time. Since
reducing her medication and becoming unwell, Angela has not felt like seeing him as much.
She is concerned that she may be losing interest in him, though she is not sure. She wonders if
her reduced interest in sex may be behind her feelings for her boyfriend and believes that the
medication has reduced her libido.
Angela has never received much help from her family because they don't agree with her
diagnosis. He father says that she is just an attention getter and that she puts it on. He says
that is why she cut herself when she was a teenager. Her father states that if she just stopped
"boozing" she wouldn't be so down and need the medication. Angela disagrees, stating that
she has been drinking to help her sleep for years and is drinking no more or less now.
Nonetheless, Angela has tried to cut down on her alcohol use over the last month and this has
interfered with her sleep.
USE ANSWER SHEET ON THE NEXT PAGE

Answers for the Individualised Assessment Exercise

1. List all possible factors influencing

2. List the most likely (causal) factors

Angela's reduced use of medication

influencing Angela's reduced use of
medication

Medication Alliance Beliefs Questionnaire
The following questions ask you about your general beliefs regarding assisting people
to make effective use of their antidepressant medications. Please indicate how
strongly you agree or disagree with these general statements by ticking the box that
best represents your judgement. Use the key below to help guide your answers.
5 = strongly agree
4 = somewhat agree
3 = neither agree nor disagree
2 = somewhat disagree
1 = strongly disagree
Strongly
disagree
1

1
2
3
4
5
6
7
8
9

I want to work with people who have medication
adherence issues.
I feel that the best that I can personally offer
people who have medication adherence issues is
referral to somebody else
I feel that there is little that I can do to help people
who have medication adherence issues
I am interested in the reasons that people have for
not using their medications and the responses that
can be made to them
I feel I know enough about the reasons why
people don't use medications to carry out my role
when working with people who have medication
adherence issues
In general, I feel that I can understand people who
have medication adherence issues
In general, one can get satisfaction from working
with people who have medication adherence
issues
I often feel uncomfortable when working with
people who have medication adherence issues
I find it difficult to have empathy for people who
have medication adherence issues

Strongly
agree

Strongly
disagree
10

I feel that I do not have much to be proud of when
working with people who have medication
adherence issues

11

I feel I know how to counsel people who have
medication adherence issues over the long term

12

In general, it is rewarding to work with people
who have medication adherence issues

13

I feel that I can appropriately advise people about
the use of their medications

14

I feel that I have a working knowledge of
medication adherence issues

15

I feel that the people that I work with believe that
I have the right to ask them questions about their
use of medications when necessary

16

I cannot understand what it is like for people who
have medication non- adherence issues

17

I feel I have a clear idea of my responsibilities in
helping people who have medication adherence
issues

18

I feel that I have the right to ask a person with
whom I am working for any information that is
relevant to their use of medications

19

All in all I am inclined to feel I am a failure when
working with people who have medication
adherence issues

20

I feel I have the right to ask the people that I work
with questions about their use of medications as
necessary

21

On the whole I am satisfied with the way I work
with people who have medication adherence
issues

22

23

I feel I know enough about the factors which put
people at risk of developing problems with the use
of their medications to carry out my role when
working with people who have medication
adherence issues
I find it hard to imagine what it might be like to
have medication adherence issues

Strongly
agree

Strongly
disagree
24

Pessimism is the most realistic attitude to take
with people who have medication adherence
issues

25

At times I feel I am no good at working with
people who have medication adherence issues

26

I sometimes feel that I do not have the skills to
manage issues related to peoples use of
medications

27

It is right to persist in trying to persuade an
individual to take prescribed medication if they
initially refuse

28

It may be appropriate for an individual to use
illicit drugs if they believe that this will help their
symptoms

29

Medication is ineffective in reducing an
individual's symptoms

30

It is not appropriate for an individual to use illicit
drugs even if they believe that this will help their
symptoms

31

Sometimes I do not have the confidence to
manage medication use issues

32

I accept the medical view that depression is an
illness

33

Medication is an essential component of any
treatment plan

34

The beneficial effects of medication outweigh the
side effects

35

It is important to actively involve people with
major depressive disorders in making decisions
about their medications

36

Taking medication prevents an individual's
symptoms of their illness returning

37

Too much discussion about medication can make
people stop using their medication

38

I expect most people with a major depressive
disorder to be non-adherent with their medication

39

I can relate to the experiences of those who have
medication adherence issues

Strongly
agree

Medication Alliance Clinician Knowledge Questionnaire
Please circle the most correct response to each question,

1. Resistance to taking medication should be seen as:
a. denial - a trait characteristic requiring confrontation;
b. needing to be met with logical argument and correction;
c. an interpersonal behaviour pattern influenced by the therapists behaviour;
d. an indication that the consumer is unable to comprehend the value of
medication;
e. an indication that you should try to work through the carers.
2. Sub-optimal use of prescribed medication:
a. is a 'normal' behaviour;
b. is almost always due to deficits in insight;
c. indicates that the consumer does not want to work with you;
d. is best responded to by the psychiatrist or treating GP;
e. is never likely to change, no matter what you do.
3. Motivation:
a. is usually absent in people with depression;
b. is something that the case manager can try to influence;
c. is a personality characteristic;
d. cannot be changed;
e. none of the above.
4. Case formulation involves:
a. identifying things that happened in the patient's developmental period that
have contributed to the current problem;
b. identifying the recent events that triggered the problem;
c. identifying the thoughts and behaviours that maintain the problem;
d. identifying 'constitutional' predisposition toward having the problem;
e. all of the above.
5. The
a.
b.
c.
d.

best way to influence medication is to:
apply cognitive behavioural therapy techniques;
educate the patient about their medications;
enlist the support of family and friends in a collaborative approach;
look for functional relationships that involve the person's use of medication
and try to influence those relationships;
e. personally administer the medication.

6. As a general rule, most therapeutic change occurs:
a. between sessions as the patient does their homework;
b. during the session;
c after therapy has been completed, when the patients use their new skills
independently;
d. when
the patient gains insight into the importance of treatment;
e. when the consulting physician is involved.

7. An illness timeline is:
a. a countdown to the next hospitalisation;
b. a method of individual education about medication use;
c. a way to explain to carers the costs of not taking medication;
d. an estimation of the period of health given optimal medication use;
e. a strategy for the determination of idiosyncratic predictors of mental health
and ill health.
8. The most important task to undertake early in Medication Alliance Therapy is:
a. making sure that the person understands the importance of continuing to use
their medications even when they are well;
b. establishing engagement with the person specific to their medication issues;
c. setting homework to help identify why they are not using their medications;
d. setting an agenda about how you will help the person use their medications;
e. all of the above.
9. In a functional analytic approach to behaviour change, the first thing to do is:
a. clearly define the behaviour;
b. determine the immediate antecedents;
c. inquire about early life experiences that might have influenced the behaviour;
d. investigate the consequences maintaining the behaviour;
e. ask carers what they think is causing the behaviour.
10. Homework:
a. should almost always be included at the end of each session;
b. should be determined by the clinician according to the therapeutic agenda;
c. should always involve the patient recording something on paper;
d. need not be reviewed if the session is 'busy';
e. none of the above.
11. Evaluation of how well your medication-related intervention is going should:
a. be undertaken in some way every session;
b. be undertaken intermittendy to see how things are going;
c. always involve formal measurement;
d. both b and c are true;
e. none of the above is true.
12. When using the illness timeline, autobiographical memory problems mean that:
a. consumers can never benefit from this process;
b. only with the aid of carers/family a timeline can be completed;
c. pictures are a better way of getting the information;
d. the use of a vertical timeline may be more appropriate;
e. none of the above.

13. Problem solving
a. involves a delineation of difficulties and brainstorming strategies to resolve
those difficulties;
b. giving consumers answers to their most pressing problems;
c. allowing consumers to make mistakes so that they have an opportunity to learn
and grow and human beings;
d. is only useful in complex cases;
e. none of the above.
14. The stress-vulnerability model suggests that we should:
a. identify consumers for whom little hope is possible;
b. focus our energy on reducing both vulnerability and stressors;
c. use psychosocial models as the primary way to manage relapse;
d. consider the value of anxiety medication to assist the consumer to reduce
stress levels;
e. none of the above.
15. The goal of cognitive behavioural therapy is to:
a. establish the consumer's biological vulnerability to mental ill health;
b. link a situation directly with the emotion that follows it;
c. identify a consumer's unhelpful thoughts and outline for the consumer
evidence against their dysfunctional beliefs;
d. teach consumers to tolerate and live with their irrational thoughts;
e. teach the consumer how to identify, reality-test and correct unhelpful thoughts
and beliefs.

Beliefs about Medication Questionnaire
Please answer the following questions about your views regarding medications in general.
These are statements that other people have made and we would like you to indicate the
extent to which you agree or disagree with them by ticking the appropriate box that best
matches your opinion. Please use the following key to guide your response:

Strongly
disagree
1 Doctors use too many
medications
2 People who take
medications should stop
their treatment for a while
every now and again
3 Most medications are
addictive
4 Natural remedies are safer
than medications
5 Medications do more
harm than good
6 All medications are
poisons
7 Doctors place too much
trust on medications
8 If doctors had more time
with patients they would
prescribe fewer
medications

Disagree Uncertain Agree

Strongly
agree

